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DEVELOPMENT OF POINT-OF-CARE ASSAYS FOR DIFFERENT BIOLOGICALLY
RELEVANT ANALYTES

by

DANDAN LIU

Under the Direction of Suri S. Iyer, PhD

ABSTRACT
This thesis focuses on the development of assays that could potentially be used in PointOf-Care (POC) diagnostics. We present our discovery and development efforts for three targets,
influenza, norovirus and inflammatory bowel disease.
Influenza is a respiratory infection caused by influenza viruses, a highly contagious
pathogen that primarily spreads through respiratory droplets. Influenza pandemics has led to
millions of deaths. A significant number of patients have complications because of secondary
infections caused by S. pneumoniae, after the initial infection caused by influenza. Thus,
differentiation of influenza and S. pneumoniae is very important for appropriate treatment options.
Here, we have synthesized fluorescent sialic acid derivatives that are cleaved by influenza
neuraminidases (NAs) and not by S. pneumoniae. We have also developed assays that could

differentiate between influenza viruses and S. pneumoniae by taking advantage of the structural
differences between NAs from these pathogens and assay conditions.
In the second project, we present our efforts to identify and develop biomarkers for
inflammatory bowel disease (IBD), which is characterized by chronic inflammation in
gastrointestinal tract. People diagnosed with IBD are required to monitor their status of
inflammation routinely. The gold standard to monitor IBD is to perform endoscopic evaluation
with biopsies. However, this method is invasive, and patients often experience pain and discomfort
during these procedures, highlighting the need for a non-invasive and cost-effective technique to
monitor inflammation. Here, we explore the use of alternate biomarkers, matrix metallopeptidase
9 (MMP-9) and tumor necrosis factor alpha (TNF-α) in stool and sera, respectively, that can
increase in inflammatory conditions. We explored the correlation between MMP-9, TNF-α levels
and severity of colitis in IL10-/- mouse model, with a view to designing an effective tool for POC
diagnostics for human IBD, since IL10-/- mouse model reflects inflammation in human IBD
patients. We also present our initial studies to detect and monitor these biomarkers using a novel
mesoporous silica bead-based method.
In the third project, we targeted human noroviruses in an effort to develop assays that could
detect noroviruses at POC. Human noroviruses are the major cause of epidemic outbreaks of
gastroenteritis. At the present time, there are no antivirals or vaccine for norovirus infection; the
treatment options are primarily supportive care, and reverse dehydration and electrolyte
abnormality. Therefore, prevention and early diagnostics of norovirus is important. When
noroviruses infect humans, it binds to human histo-blood group antigens (HBGAs). However, the
interactions between norovirus and HBGAs are poorly understood. Here, we have studied the
interactions between norovirus virus like particles (VLPs) and chemically synthesized HBGAs by

surface plasmon resonance (SPR) with the ultimate goal being able to use some of these
carbohydrates as recognition molecules in diagnostics to capture norovirus. We found that the
interactions between HBGA and VLPs are complex and highly dependent on the structure of the
VLP and the carbohydrate.
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1.1

CHAPTER 1 POINT-OF-CARE TESTING

Introduction
This thesis focuses on the development of assays that could potentially be used in Point-

Of-Care tests (POCTs). Therefore, in this chapter, we discuss some of the requirements of POCTs.
As defined by the National Academy of Clinical Biochemistry (NACB), POCT refers to any
testing performed outside of the traditional, core and central laboratory. It is an excellent method
to provide laboratory testing or near the site of patient care so that medical treatment does not have
to be delayed. POCT can be undertaken in many places, for example, home use, pharmacy,
ambulance, nursing home, primary care, health clinic, major hospital and workplace drug
screening, Table 1.1 showed the application of POCT. The analytical process of POCT in
healthcare is innovative and it can offer other options for disease prevention, diagnosis and patients
monitoring.1 POCT systems make up an important part of the in-vitro diagnostics market and the
global market is estimated to reach $ 38 billion by 2022 from $ 23 billion in 2017. 2 A major
segment of the POCT market comes from the blood glucose strips and test meter for diabetes,
which utilizes the electrochemical biosensor for detection.3
Table 1.1 The application of POCT in different places. Table is taken from publisher with
permission.4
ICU/operating room

Emergency department

Outpatient department
Ambulance

Critical care testing:
Blood gases, electrolytes, lactate
Emergency parameters:
Blood gases, electrolytes, lactate
Monitoring parameters:
Glucose, HbA1c
Critical care testing:
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Glucose, cardiac markers
Physician’s practice

Patient at home

Monitoring parameters:
Glucose, HbA1c, global coagulation tests
Self-monitoring:
Glucose, global coagulation tests

Several reasons could be contributed to the fast growth of POCT systems market.
Improvement in analytical methods; increasing demand for continuous measurement; increasing
patients and consumer interest; a rapidly increasing demand in the outpatient setting. There are
numerous POCT devices developed and different biosensor techniques have been applied in the
test, such as, electrochemical biosensor, optical biosensor and microgravimetry biosensor.5, 6 The
POCT devices can be classified as: qualitative device (such as lateral flow assays), benchtop
instrument (such as spectrophotometric devices, chemistry test strips), viscoelastic coagulation
analyzers7 (such as bleeding time testing) and continuous testing device8 (such as Free Style Libre
from Abbott Diabetes Care).
An important factor to be considered for widespread use of POCT devices was developed
by the WHO. This ASSURED (Affordable, Sensitive, Specific, User-friendly, Rapid and robust,
Equipment-free and Deliverable to end-users) criteria provided by World Health Organization
(WHO) can be used to identify the most appropriate POCT for the resource-limited areas .9 In
addition, WHO also provided six steps for selecting an appropriate in vitro diagnostic test10, which
is shown in Table 1.2.
Table 1.2 Six steps in selecting an appropriate diagnostic test. Table is taken from
publisher with permission.11
Step 1

Define the purpose of the test

Step 2

Review the market and check each product’s specification
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1.2

Step 3

Review the test’s regulatory approval

Step 4

Obtain data on the diagnostic accuracy of the test under ideal conditions

Step 5

Obtain data on the diagnostic accuracy of the test in clinical practice

Step 6

Monitor the test’s performance in routine use

Biosensor Technology
There are several techniques used to develop POC diagnostics. Given below are some of

the techniques used for analyte sensing. These examples are not meant to be a comprehensive
review but are chosen to give the reader a broad view of the technologies could be used to develop
POCTs.
1.2.1

Electrochemical sensor

Electrochemical sensor is based on transducing biochemical reactions to electrical
signals.11 Normally, the sensor consists three electrodes: reference electrode, working electrode
and counter electrode. A reference electrode commonly made from silver metal coated with silver
chloride (Ag/AgCl) or saturated calomel electrode (SCE); a working electrode consists conductive
materials, such as gold, carbon and platinum; a counter electrode connects the electrolytic solution
to apply the current to the working electrode.5 While a two electrode system only need working
electrode and reference electrode. The signal comes from the electron exchange between chemical
component and the electrode. There are mainly three types of electrochemical sensors:
amperometric sensor, potentiometric sensor and conductometric sensor.
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Figure 1.1 The principle of electrochemical sensor. Figure is taken from publisher with
permission.12
Amperometric sensor continuously measures the current generated by the electrochemical
oxidation or reduction at a given potential which is maintained at the working electrode as regards
a reference electrode.13 The measured current is proportional to the analyte concentration. The
fixed potential in the detection leading to a negligible current needed to apply the potential to the
system, minimizing the background signal, which makes it excellent sensitivity. This technique is
applied in glucose meter to measure blood glucose and oxygen electrode is applied. Potentiometric
sensor measures the potential change at the working electrode in respect with the reference
electrode when no significant current between them.14 The main types of potentiometric transducer
electrodes are: transmembrane potential (Based on the accumulation of a potential from a sensor
membrane), electrode potential (Based on a potential from the electrode, similar to transmembrane
potential) and field effect transistor (FET). Conductometric sensor measures the change of electric
conductivity from chemical reaction at stable voltage.15
Table 1.3 Different types of electrochemical sensor.
Electrochemical sensor type

Principle

Amperometric sensor

Oxidation / reduction
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Potentiometric sensor

Electric potential

Conductometric sensor

Electric conductivity

1.2.2

Optical Sensor

Optical biosensor measures the interactions of analytes based on the measurement of
photons in the process. The detection involving the measurement of fluorescence, reflection,
absorbance, Förster Resonant Energy Transfer (FRET) and refractive index. Most commonly used
optical techniques including fluorescence, absorbance, luminescence. They are widely used in the
immunoassay, whereas they require the use of appropriately labeled substances. The label-free
optical surface techniques are barely used in POC, although they have excellent analytical
sensitivity. For example, surface plasmon resonance (SPR) is a label-free, quantum-physical
phenomenon-based sensor.16 It takes advantage of total reflection between two mediums, causing
the formation of evanescent waves, which results in the excitation of electron on the gold and form
plasmon resonance. When the analytes binding with the immobilized ligand, the refractive index
changes leading to the change of signal.
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Figure 1.2 The principle of lateral flow assay. Figure is taken from publisher with
permission.17
1.2.3

Microgravimetry sensor

Microgravimetry biosensor is mass sensitive sensor, which can be classified into three
types according to the signal transduction methods: Quartz crystal microbalance, surface acoustic
wave-based systems and microcantilevers.18 In the quartz crystal microbalance method, the surface
of crystal is covered with a thin gold in its resonant frequency by changing voltage. The signal
resonant frequency is proportional to the mass of chemicals on the surface. In the surface acoustic
wave system, the surface wave is excited electrically by interdigital transducers. The acoustic
waves are restricted on the surface and decay as far away from the surface. Microcantilever
measures the changes of cantilever bending or vibrational frequency. When a specific mass of
material is absorbed on the surface, the bending will change.19

7

Figure 1.3 The principle of Quartz crystal microbalance immunosensor. Figure is taken
from publisher with permission.20
1.3

POCT Application
1.3.1

Patient self-monitoring

Blood glucose meter is one of the most commonly used self-monitoring device. About 90%
of blood glucose test is to monitor the glucose level of diabetes and modify the medication for the
patients. The first blood glucose meter and glucose self-monitoring system were developed by
Anton H. Chemens. Now glucose meter has been widely used in identifying hypoglycemia and
hyperglycemia. The measurement of glucose is based enzymatic assay reaction.3 On the glucose
meter strips, glucose is oxidized to gluconic acid by glucose oxidase in the presence of water and
oxygen. The enzyme cofactor flavin adenine dinucleotide (FAD) receives the first electron and is
reduced to FADH. Followed by FADH is oxidized by oxygen and form H2O2, the electron transfer
can be measured by electrochemical methods. The mechanism was shown in Figure 1.4.
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Figure 1.4 The mechanism of glucose meter. Figure is taken from publisher with
permission.21
International Normalized Ratio (INR) was introduced by WHO in 1983 to measure the
anticoagulation treatment with vitamin K antagonist. The prothrombin time was measured and
converted to INR based on the thromboplastin in the test. The value of 1.0 in INR is for normal
coagulation individuals not on medication. When patients are treated with vitamin K antagonists,
the value increases, which ranges from 2 to 3.
1.3.2

Emergency care

Preclinical rescue systems include emergency ambulances and vehicles staffed by
clinicians. The responsibility of emergency clinician is to restore and stabilize the vital functions
of the patient. POCT can do initial diagnosis and is helpful for quick and efficient treatment
decision. The applications of POCT in emergency department include measure acid-base status,
blood gases, CO oximetry, electrolytes, metabolites, cardiac markers.
Table 1.4 Mean analytical performance of common methods for POCT. Table is taken from
publisher with permission.22
Analytes

Analytical performance

Blood gas and electrolytes

Optimal

Cardiac markers

Variable

Basic biochemistry

Acceptable

Inflammation markers

Acceptable
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Complete blood count

Acceptable

Coagulation

Acceptable

Pregnancy test

Acceptable

Urinalysis

Acceptable

Infection, molecular

Acceptable

Serology

Acceptable

Drugs of abuse

Limited

Toxicology

Limited

1.3.3

Physician’s practice

POCT is mainly used in smaller hospital, where a 24-hour laboratory service is not
available. The reasons to apply POCT in hospital are the waiting time from the central laboratory
is normally too long; in the hospital without central laboratory, the detection can be carried out
with POCT. Some examples of POCT in the physician practice was listed in Table 1.4.
Table 1.5 Examples of POCT in the physician practice setting. Table is taken from
publisher with premission.4
Urologist

Prostate-specific antigen for cancer screening

Gynecologist

Human chorionic gonadotropin for pregnancy testing

Cardiologist

Brain natriuretic peptide for monitoring the clinical course in patients
with heart failure

Oncologist

Blood count prior to chemotherapy

Sports physician

Lactate as performance check

General practitioner

INR for monitoring anticoagulation

Diabetologist

Blood sugar and HbA1c for monitoring the clinical course of blood
glucose control

Pediatrician

Rapid streptococcal detection test prior to antibiotic therapy

Nephrologist

Albumin as microalbuminuria screening in diabetic nephropathy

Psychiatrist

Drug screening during therapy for withdrawal
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1.4

Summary

Described in the previous section is a snapshot of some of the techniques used in POCTs.
The goal in our research group is to develop POC assay to detect biological relevant analytes. I
was involved in three of those projects: development of POC assay to detect influenza, norovirus
and inflammatory bowel disease.
To detect influenza, we have synthesized fluorescent sialic acid derivatives that are cleaved
by influenza neuraminidases (NAs) and not by S. pneumoniae. We have also attempted to develop
assays that could differentiate between influenza viruses and S. pneumoniae by taking advantage
of the structural differences between NAs from these pathogens. we can perform this assay with
handheld fluorometer. Handheld fluorometer is a small, lightweight and highly durable equipment,
which is ideal for POC measurement. Upon cleaving of the substrate by influenza, the fluorophore
can be released and detected by handheld fluorometer in seconds. This allows patients self-test at
home or in low resource settings.
In the second project, we present our efforts to identify and develop biomarkers for
Inflammatory bowel disease (IBD). Here, we explore the use of alternate biomarkers, MMP-9 and
TNF-α, that can increase in inflammatory conditions. We explored the correlation between MMP9, TNF-α levels and severity of colitis in IL10-/- mouse model, with a view to design an effective
POCT for human IBD, since IL10-/- mouse model has similar condition with human IBD. We also
present our initial studies to detect and monitor these biomarkers using a novel mesoporous silica
bead-based method, which can be used for POCT.
In the third project, we targeted human noroviruses in an effort to develop assays that could
detect noroviruses at POC. We studied the interactions between norovirus virus like particles
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(VLPs) and chemically synthesized HBGAs by surface plasmon resonance (SPR) with the goal
being able to use some of these carbohydrates as recognition molecules in diagnostics to capture
norovirus. We found that the interactions between HBGA and VLPs are complex and highly
dependent on the structure of the VLP and the carbohydrate. It can be applied to FilmArray™
Gastrointestinal (GI) Panel quick test. Different types of HBGAs can be attached on the bottom of
array, when the norovirus flow through the array, it can be captured by HBGAs. According to the
binding pattern results, different genotypes of norovirus can be identified.
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CHAPTER 2 FLUORESCENT SIALIC DERIVATIVES FOR THE SPECIFIC
DETECTION OF INFLUENZA VIRUSES

* Most of the work described in this chapter has been published in the publication:
Dandan Liu, Xikai Cui, Abasaheb N. Dhawane, Vasanta Chivukula, Suri S. Iyer*.
Fluorescent Sialic Derivatives for the Specific Detection of Influenza Viruses. Bioorganic
& Medicinal Chemistry Letters, 2019, 29 (24), 126773.

2.1

Influenza Introduction
2.1.1

Influenza epidemiology

Influenza is a respiratory infection caused by influenza virus, which is highly contagious
and spread through respiratory droplets. Influenza outbreaks lead to millions of deaths and
hospitalizations. The first pandemic influenza was reported from Russian in May 1889.23 At first
it spreads slowly, then it began to spread in lighting speed in October 1889. Till spring 1890, it
spread through the whole world. It killed 1 million of people worldwide.23 Around 30 years later,
another pandemic influenza appeared in 1918 (Spanish flu) which was caused by influenza H1N1.
It spread very fast, leading to estimated 50-100 million deaths.24 Most deaths in this pandemic
were caused by secondary bacterial pneumonias, which lagged by approximately 7-10 days after
influenza.25 After around another 30 years, a new pandemic H2N2 influenza outbreak in Guizhou,
China, leading to estimated 1.1 million deaths worldwide, which is known as Asian flu.26 Most of
the deaths are influenza and pneumonia related. In a decade, pandemic influenza happened again
in Hongkong in 1968.27 This pandemic was caused by H3N2 influenza, which is believed to rise
from H2N2 through a process antigenic shift, in which hemagglutinin antigen on the influenza
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went through a genic mutation to H3 antigen. Although fewer deaths in this Hongkong flu, H3N2
is very contagious and still considered as seasonal flu.28 There’s no pandemic influenza after a
long time until 2009, which was caused by swine-origin H1N1 flu, very different from HIN1 from
1918. Less people (estimated 18,500 – 150,000) were killed by swine flu due to the flu vaccine.29
Although pandemic influenza doesn’t occur every year, seasonal flu typically peaks between
December and February each year and kills around 291,000-646,000 people worldwide.29
2.1.2

Influenza life cycle

There are three transmembrane proteins on the surface of influenza virus: haemagglutinin
(HA), neuraminidase (NA) and matrix 2 (M2).30 When influenza virus infects host cell, the HA on
the surface will recognize the terminal sialic acid of glycoconjugates on the surface of host cell
and enter the cell by endocytosis. It has low pH around 5 to 6 in the endosome, which triggers the
fusion of virus.31 The acidic environment also opens M2 ion channel to acidify the viral core to
release viral ribonucleoprotein (vRNP), hence the vRNP can be free to enter the cytoplasm of the
host cell.32
The influenza virus contains negative sense viral RNA.33 After the vRNP enters the
nucleus, it can transcribe into mRNA and translate to make viral proteins, also it can be replicated
to make more vRNP. Then the viral proteins and vRNP assembly to make viral progeny.32 The
progeny will be budding to exit to the cell and the NA will cleave the sialic acid residues to release
the newly formed viral particles. These particles will continue to infect the other cells. (Figure
2.1)
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Figure 2.1 Life cycle of influenza virus. Figure is modified from journal with permission.34
2.1.3

Influenza proteins

In the process of influenza infection, there are two proteins, haemagglutinin (HA) and
neuraminidase (NA), play important roles and they are also important biomarkers to detect and
treat influenza infection.
HA
HA is a homotrimer that can bind to sialic acid receptor on the surface of host cell and
mediates the release of influenza vRNP to cytoplasm.33 HA processor is made of two subunits:
HA1 and HA2, they are connected by disulfide bond.35 HA1 contains sialic acid receptor domain,
which allows the virus to enter the host cells by endocytosis. HA2 contains fusion peptide which
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can attach to the endosomal membrane to promote the releasing of vRNP to cell cytoplasm.36 There
are two major binding between sialic acid and glycoproteins: α (2,3) linkage and α (2,6) linkage.37
They are very important for the specificity of HA binding to sialic acid receptor. Influenza virus
from human only recognizes α (2,6) linkage, influenza from avian only recognizes α (2,3) linkage,
influenza from swine recognizes both.37 That explains why swine influenza is more contagious
and harmful.

Figure 2.2 α (2,3) linkage and α (2,6) linkage of sialic acid.
When HA binding to the sialic acid unit on the host cell, a receptor-mediated endocytosis
process helps the virus get into the host cell. The pH (5~6) of the endosome will trigger the fusion
process and induce the conformational changes in HA0 to expose the HA2 fusion domain. The
HA2 is released to the endosomal membrane and helps the endosomal membrane contact with the
viral.38 The low pH environment of the endosome is important to induce the HA0 conformation
changing to expose the HA2 fusion peptide. Another biological process is also triggered by the
low pH environment of the endosome, the M2 ion channel on the surface of the virus opens up in
low pH environment. This process will acidify the virus core and help the release of the vRNP
from M1, which is the M1 part of the ion channel. Consequently, the vRNP is free to enter to the
cytoplasm of the host cell.39
NA
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Influenza NA is a homo tetramer, which consists four identical subunits (Figure 2.3).40
There are usually 50~100 copies of NA on virus surface. NA is essential for the influenza virus
leaving the host cell by catalyzing hydrolysis of both α (2,3) and α (2,6) linkages of glycosidic
bonds.40 NA is an exoglycohydrolase which hydrolyzes terminal sialic acid residues from
glycoproteins and glycoconjugates.41 Cleavage of terminal sialo side initiate with the binding to
the active sites of NA. After binding, the stable chair conformation is forced into a less stable boat
conformation due to the highly conserved triarginyl cluster (Arg-118, Arg-292, and Arg-371).
Conformational changes facilitate the leaving group falling down and form an oxocarbocation ion
intermediate, a sialosyl cation. The sialosyl cation undergoes a nucleophilic attack to form a
glycosyl-enzyme intermediate. The glycosyl-enzyme intermediate breaks to generate a sialosyl
cation again, where it undergoes nucleophilic attack by a water molecule to form an α-Neu5aAc
as the initial product. The α-Neu5Ac product is further isomerize into β-Neu5Ac, the more
thermodynamically favored product.41

Figure 2.3 3D dimension of influenza NA binding with sialic acid. The structure was
downloaded from NIH PDB database (PDB: 1NNA).40 Different monomers were shown in green,
cyan, purple and yellow colors, sialic acid molecule was shown in red sphere.
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2.1.4

Influenza therapeutics

Several FDA-approved anti-influenza antivirals have been used for influenza treatment.
These drugs can be divided into three groups: the M2 ion channel blockers, the neuraminidase
inhibitors (NAIs) and the virus polymerase inhibitors.34, 42 In recent years, influenza virus has
developed high assistance to some of the drugs, hence some of them are no longer used.
M2 ion channel blockers
M2 ion channel is a single-pass membrane protein, which is important in the process of
unpacking viral genome into cell.43 The adamantane-based anti-influenza drugs amantadine and
rimantadine (Figure 2.4) target the M2 ion channel to block it, that have been used as first choice
antiviral drugs for influenza A virus.44 However, influenza A H3N2 and H1N1 are highly resistant
to these drugs.45 The center for disease control and prevention (CDC) does not recommend these
antiviral drugs to treat influenza anymore.

Figure 2.4 The structure of amantadine and rimantadine.
NAIs
NAIs target neuraminidase and prevent its cleavage, therefore inhibiting the release of viral
progeny.46 FDA approved NAIs include oseltamivir, zanamivir, peramivir and laninamivir, they
are sialic acid analogues, that can specifically bind to neuraminidase enzyme active site.42, 47
Oseltamivir (Figure 2.5A) and zanamivir (Figure 2.5B) are globally available.
Oseltamivir is a prodrug of oseltamivir carboxylate, a potent inhibitor for neuraminidase of
influenza A and B. Oseltamivir is the first approved NAI drug, the bioavailability of its active

18
metabolite is around 80%.48 Zanamivir is approved for inhalation delivery with intravenous
administration due to its low oral bioavailability. Intravenous zanamivir can be used for seriously
ill patients with influenza, especially those patients resist to oseltamivir.49 Peramivir (Figure 2.5C)
is approved in China, Japan, South Korea, and the United States. It also has low bioavailability
and is therefore delivered intravenously. Peramivir-treated patients have rapid and greater
reduction of influenza A and B viral titers than oseltamivir in the first 48 hours.50 Antiviral
resistance to zanamivir, oseltamivir and peramivir is very low for current influenza strains.42

Figure 2.5 The structure of oseltamivir carboxylate, zanamivir and peramivir.
Laninamivir octanoate (Figure 2.6) was approved in Japan in 2010 to treat influenza A and
B. It is prodrug, which converts to its active form laninamivir in lung. Laninamivir octanoate
performs as inhalation delivery, with long-lasting action (Half-life of as long as 41.4 hours),
displays antiviral effect for treatment of oseltamivir-resistant H275Y-mutated virus.47
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Figure 2.6 Prodrug laninamivir octanoate (A) and its active form laninamivir (B).
2.1.5

Influenza diagnostics

Diagnostic tests for influenza basically include viral culture, molecular assays and antigen
detection assays.51,

52

Molecular assays include rapid molecular assays, reverse transcription

polymerase chain reaction (RT-PCR and other nucleic acid amplification assays). Antigen
detection assays include rapid influenza test and immunofluorescence assays.
Viral culture
Viral culture test, original from 1940s, is highly sensitive and selective, and it is one of the
gold standard method to detect influenza.53 This method uses infectious samples to inoculate with
permissive cell lines or embryonated eggs, propagation for 7 - 10 days to monitor development of
cytopathic effect, then confirm influenza infection with staining, immunofluorescence microscopy
or erythrocytes hemadsorption.54 Influenza virus isolation using this approach is usually performed
on two types of cell lines: first, established cell lines, such as Madin Darby canine kidney (MDCK),
A549, mink lung epithelial cell line (Mv1Lu), rhesus monkey kidney (LLC MK2), and buffalo
green monkey kidney (BGMK); second, primary cell lines, such as rhesus monkey kidney (RhMK)
or African green monkey kidney (AGMK).55 This assay has high specificity and requires welltrained personnel and takes long time to perform.56
Molecular assays
Molecular assays include RT-PCR and other nucleic acid amplification assays. RT-PCR
can identify influenza viral RNA in respiratory specimens. It is believed to be most powerful
nucleic acid-based test (NAT) approach to detect influenza.55 Other nucleic acid amplification
assays include ligase chain reaction, sequencing-based tests and loop-mediated isothermal
amplification-based assay (LAMP), etc.57-59 The basic procedure for RT-PCR includes extraction

20
of RNA from specimens and reverse transcript viral RNA to single-stranded complementary DNA
(cDNA) using enzyme reverse transcriptase, and product amplification with fluorescent
detection.60 This method is highly sensitive and selective, while it takes few hours and it is the
most expensive test, also it requires well-trained personnel.60
Antigen detection assays
Antigen detection assays include rapid influenza tests (RIDTs) and immunofluorescent
assays. RIDTs are antigen-based tests developed to rapid diagnose influenza in around 15 min.52
Several FDA-approved RIDTs are available, such as: BD Directigen EZ Flu A+B test (Becton
Dickinson), BinaxNOW Influenza A&B (Inverness Medical), and QuickVue Influenza A+B Test
(Quidel), but none of these can differentiate different A subtypes.52, 61 Immunofluorescent assays
detect antigen with fluorescence, which takes around 1 hour.51 And it cannot distinguish different
A subtype either. These assays have high selectivity and medium sensitivity.62
Summary
All these tests above are expensive and none of them can measure drug susceptibility
rapidly in a POC setting. The lack of good rapid diagnostic tests leads to asymptomatic treatment
and overuse of drugs, which increases drug resistance.63 Additionally, the initial infection caused
by the virus often leads to secondary infection caused by bacterial pathogens.64 It is very important
for a physician to ascertain if the infection is viral or bacterial, because the treatment is different.
For influenza infections, antiviral drugs like Tamiflu or Relenza are prescribed;65 in contrast, for
bacteria, antibiotics such as Azithromycin Zpak, is prescribed.66 Secondary infections can increase
burden, for example, infections caused by Streptococcus pneumoniae, can lead to otitis media,
especially in immunocompromised people and children five years old or younger.67 It takes 1–4
days for symptoms of influenza related sickness to appear after exposure to the virus. The time
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when secondary infection due to S. pneumoniae or other bacteria occurs is not very clear, as the
interplay between viral, bacterial and the host immune system is complex68 and to compound the
issue further, overall morphological symptoms due to viral/bacteria are quite similar. Thus, by the
time the patient enters the clinic, it is unclear if the patient is suffering from viral, bacterial or
coinfections. Therefore, differentiate between influenza and secondary bacterial infection is
important.
We recently developed an electrochemical assay to detect enzymes using a repurposed
glucose meter. Briefly, we developed substrates bearing a glucose molecule and expose it to
samples containing the enzyme.69 If enzyme is present and is active, glucose is released, which
can be quantified using a glucose meter and correlated to the activity of the enzyme. Our first target
was influenza virus; we synthesized sialic acid bearing molecules that release glucose.69 These
molecules, when exposed to NA (or sialidase) from any source resulted in release of glucose,
which was detected using a glucose meter. In further iterations, we demonstrated that molecules
like galactose70 and paracetamol71 can also be detected using glucose meters; and we synthesized
sialic acid derivatives that were highly specific for influenza viruses. Similar biochemiluminescent
molecules, when exposed to influenza or S. pneumoniae, were cleaved only by influenza viral
strains with high specificity.72 By using a combination of natural and modified sialic acid
derivatives, we could differentiate between influenza and S. pneumoniae.70 While electrochemical
detection using repurposed glucometers are very valuable in diagnostics, fluorescence based
detection of pathogens cannot be understated, especially when it is integrated with smartphones.73
Here, we report a fluorescence based assay that could lead to the accurate detection of influenza
virus by exploiting structural differences between NAs from influenza and S. pneumoniae.
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2.2

Experiment Design

Figure 2.7 Electrochemical assay to detect enzymes using glucose meter. Figure is taken
from publisher with permission.74
Previously, we have developed electrochemical assay to detect NA using a repurposed
glucose meter (Figure 2.7). Briefly, we developed a substrate bearing a glucose molecule, which
can be cleaved by NA and release glucose that can be detected by glucose meter.69 By using a
combination of natural and modified sialic acid derivatives, we could differentiate between
influenza and S. pneumoniae.70 Electrochemical assay plays an important role in POC diagnostics,
while the fluorescent assay can’t be understated. Here we report a fluorescent assay to detect
influenza accurately by exploiting the structure difference between influenza NA and S.
pneumoniae NA.74
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Figure 2.8 Sialic acid derivatives for influenza and S. pneumoniae. When the substrate
MUNANA is cleaved by influenza or S. pneumoniae, 4-MU is released and detected at 360/460
nm. The substrate MUNANA (4,7 OMe) only can be cleaved by influenza and release 4-MU. Figure
is taken from publisher with permission.74

A

B
B

C

Figure 2.9 The disulfide bonds in NA monomer from S. pneumoniae and influenza virus.
The disulfide bonds in NA monomer from S. pneumoniae and influenza virus. The structures are
downloaded from NIH PDB database. The surface is showed in blue color, the disulfide bond is
showed in red color. A. The structure of S. pneumoniae Nan A monomer (PDB: 2ya5) which shows
no disulfide bond. B. The structure of H1N1 NA monomer (PDB: 3ti6) which shows eight disulfide
bonds, four of them are buried inside, the other four are exposed on the surface. C. The structure
of H3N2 NA monomer (PDB: 4gzp) which shows nine disulfide bonds, four of them are buried
inside, the other five are exposed on the surface. Figure is taken from publisher with permission.74
2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (MUNANA) and synthetic sialic
acid derivative substrate, MUNANA (4,7 OMe), were used to detect influenza and S. pneumoniae.
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Because the binding pocket of influenza NA is considerably larger than S. pneumoniae NA,
especially in 4 and 7 positions. Therefore, we synthesized a fluorescent sialic acid derivative
bearing OMe groups at the 4 and 7 positions. The natural substrate MUNANA (Figure 2.8) and
sialic acid derivative, MUNANA (4,7 OMe) (Figure 2.8) were exposed to different influenza virus
strains and S. pneumoniae and the fluorescence was recorded for 2 hours. Next, we attempted to
destroy the activity of influenza with high pH since it’s reported high pH can reduce the activity
of influenza. Also, we used dithiothreitol (DTT) to break the disulfide bonds in influenza NA.
Because there are several disulfide bonds in influenza NA, four of them are exposed on the surface
(Figure 2.9 B and C). When the bond was broken, the structure of influenza NA can be destroyed,
results in the minimal or no activity of influenza NA. While S. pneumoniae NA doesn’t contain
any disulfide bond (Figure 2.9 A), whose activity will have negligible change.
2.3

Results and Discussions
The X-ray crystal structure shows that influenza NA has a larger binding pocket than S.

pneumoniae NA. (Figure 2.10) Although both influenza and S. pneumoniae NA can cleave natural
substrate MUNANA, the MUNANA (4,7 OMe) bearing OMe group at 4 and 7 positions can only
cleaved by influenza NA. To his end, MUNANA (4,7 OMe) was synthesized as Scheme 2.1.
A

B
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Figure 2.10 The binding pocket of NA complexed with sialic acid downloaded from NIH
PDB database and PyMOL was used to show the surface and binding pocket. The binding pocket
of NA complexed with sialic acid downloaded from NIH PDB database and PyMOL was used to
show the surface and binding pocket. The carbon atom was showed in green color, the oxygen
atom element was showed in red color, the nitrogen atom was showed in blue color. A. The binding
pocket of influenza NA (PDB: 4gzq). B. The binding pocket of S. pneumoniae NA (PDB: 3h72).
Which shows the binding pocket of influenza NA is larger than S. pneumoniae NA. Figure is taken
from publisher with permission.74
Briefly, we introduced the methoxy groups to the 4 and 7 positions of protected sialic acid
before coupling to 4-Methylumbelliferone sodium salt acceptor. The known compound, 2-1, is
reacted with 4-methylumbelliferone sodium salt to yield compound 2-3 in high yield. The α
linkage was confirmed by the H3eq peak at 2.8 ppm in the 1H NMR spectroscopy. Deprotection of
the acetate and ester groups resulted in the desired compound MUNANA (4,7 OMe), which was
characterized extensively by NMR and mass spectroscopies.

26
Scheme 2.1 Reagents and conditions: a) EtOAc, TBAHS, Na2CO3, RT, 16 h, 60%; b) i)
NaOMe, MeOH, RT, 30 min; ii) 0.05 M NaOH in H2O, RT, 2 h, 84% yield after two steps. Scheme
is taken from publisher with permission.74
Next, we tested the enzyme activities of influenza NA and S. pneumoniae NA cleaving
natural substrate MUNANA in different pH. Inactivated A/Aichi/2/1968 H3N2 (sample AC),
A/Winsconsin/15/2009 H3N2 (sample WS), A/Netherlands/2629/2009 H1N1 (sample NL), S.
pneumoniae B (sample SB) were used for the experiment. The result was shown in Figure 2.11.
Both influenza and S. pneumoniae can cleave MUNANA in different pH. Although higher pH can
decrease the activity of influenza, it can’t destroy its activity. However, when modified sialic acid
derivative MUNANA (4,7 OMe) was used, only influenza can cleave it (Figure 2.12), which
demonstrates the high specificity of MUNANA (4,7 OMe) to influenza. Our results are similar to
previous reports that introduction of larger groups at the 4 and 7 positions of sialic acid make the
compounds highly specific towards influenza virus. Next, we attempted to identify conditions
where fluorescence would be realized upon exposure to S. pneumoniae and not influenza. Because
activity of all NAs decreased at higher pH, NAs from these influenza viral strains still retain their
activity. Therefore, we can’t use this condition to differentiate influenza and S. pneumoniae.
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Figure 2.11 Detection of influenza and S. pneumoniae with natural substrate MUNANA.
Sample AC, WS, NL and SB were incubated with different buffers (pH = 5.5, pH =7, pH = 8.5, pH
= 10) for 30 min. Then MUNANA was added, the fluorescence intensity was detected at 37℃, 360
nm/460 nm for 2 h. Then 1 M, 100 µL tris solution was added, fluorescence intensity was detected
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at 37⁰C, 360 nm/460 nm for 10 min. All experiments were performed in triplicate. Figure is taken
from publisher with permission.74
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Figure 2.12 Detection of influenza or S. pneumoniae by MUNANA (4,7 OMe) in different
pH. The influenza or S. pneumoniae samples were incubated in MUNANA (4, 7 OMe) solution
with different buffers (pH = 5.5, pH =7, pH = 8.5, pH = 10), the fluorescence intensity was
detected at 37℃, 360 nm/460 nm for 2 h. Then 1 M, 100 µL tris solution was added, fluorescence
intensity was detected at 37⁰C, 360 nm/460 nm for 10 min. All experiments were performed in
triplicate. Figure is taken from publisher with permission.74
Next, we used DTT, a reducing agent can reduce disulfide bond, to cleave the disulfide
bonds present in influenza NA not S. pneumoniae NA. (Figure 2.9) From the X-ray structure of
influenza H1N1 NA and H3N2 NA, there are eight disulfide bonds in one monomer of H1N1
influenza NA, nine disulfide bonds in one monomer of H3N2 NA.75-77 Four of them are buried
inside the enzyme, whereas the others are exposed on the surface, which can be reduced by DTT,
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resulting in the deactivation of NA. Upon this fact, we introduced DTT to tris buffer (pH=10),
used influenza and S. pneumoniae to cleave the natural substrate MUNANA, resulting in minimal
or no activity in influenza. In the contrast, S. pneumoniae still can cleave the substrate. (Figure
2.13)
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Figure 2.13 The results for the influence of DTT. The influenza or S. pneumoniae samples
were incubated in MUNANA solution with or without DTT. After 2 h, 1 M, 100 µL tris solution
was added, fluorescence intensity was detected at 37⁰C, 360 nm/460 nm for 10 min. All
experiments were performed in triplicate. Figure is taken from publisher with permission.74
2.4

Conclusion
We have designed fluorescent molecules specific for influenza virus. Influenza is very

contagious infection, which leads to death for patients of weak (Children and senior citizens) or
compromised immune systems (Patients with human immune deficiency virus, tuberculosis or
organ transplants). Influenza infection is always companied with S. pneumoniae infection, which
results in a secondary infection. Hence early detection and differentiation of influenza and S.
pneumoniae is important for treatment. We have attempted to exploit structural differences
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between S. pneumoniae and influenza neuraminidases to develop assay conditions to specifically
detect S. pneumoniae with limited success.
We have been developing POC diagnostics using glucose meters for the past several years.
Our previous detection strategy involved the development of glucose or galactose-based
substrates. The exposure of these substrates to enzymes or pathogens released glucose or galactose,
which was readily detected using a personal glucose meter.69 Afterwards, we have developed
paracetamol-based substrate. Which can remove the background of glucose in human blood and
lead to a higher sensitivity. However, none of those can detect S. pneumoniae specifically when
there are influenza resistant strains exist. Here we took advantage of the structure differences
between influenza and S. pneumoniae NA, use DTT to break the disulfide bonds in influenza NA,
leading to the minimum the activity of influenza. Hence, we can detect S. pneumoniae specifically
with limited success.
In the future, we will optimize the DTT condition to minimize the activity of influenza NA,
make the activity destroyed completely. Afterwards, we can perform this assay with handheld
fluorometer. Handheld fluorometer is a small, lightweight and highly durable equipment, which is
ideal for quick in situ measurement. Upon cleaving of the substrate by influenza, the fluorophore
can be released and detected by handheld fluorometer in seconds. This allows patients self-test at
home.
2.5

Experimental
2.5.1

Synthesis and characterization

General:
Chemical reagents were of analytical grade, used as supplied, without further purification
unless indicated. The acidic ion exchange resin used was Amberlite® IR-120 (H+) resin.
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Analytical thin layer chromatography (TLC) was performed on silica gel 230-400 mesh (Silicycle,
Quebec City, Canada). Plates were visualized under UV light, and/or by staining with acidic
CeH8Mo3N2O12, followed by heating. 1H and 13C NMR spectra were recorded on Bruker 400
MHz spectrometer. Chemical shifts are reported in δ (ppm) units using 13C and residual 1H signals
from deuterated solvents as references. Spectra were analyzed with MNova® (Mestrelab Research,
Escondido, CA, USA). Electrospray ionization mass spectra were recorded on a Micromass QT 2
(Waters) and data were analyzed with MassLynx® 4.0 (Waters, Milford, MA, USA) software.
Reported yields refer to spectroscopically and chromatographically pure compounds that were
dried under high vacuum (10–2 mbar) before analytical characterization, unless otherwise
specified.
Abbreviations:
Ethyl acetate, EtOAc; Tetrabutylammonium hydrogen sulfate, TBAHS; sodium carbonate,
Na2CO3; Sodium methoxide, NaOMe; Methanol, MeOH; Sodium hydroxide, NaOH; 4methlumbelliferone, 4-MU; Dichloromethane, DCM; MUNANA (2′-(4-Methylumbelliferyl)-αD-N-acetylneuraminic acid sodium salt hydrate).
2-(4-Methylumbelliferyl)-5-acetamido-8,9-di-O-acetyl-4,7-di-O-methyl-D-glycero-αD-galacto-nonulopyranosidonate (2-3)

To a solution of 2-2 72 (60 mg, 0.13 mmol) in ethyl acetate (5mL) was added a solution of
2-1 (56 mg, 0.26 mmol) and TBAHS (53 mg, 0.15 mmol) in 1M solution of Na2CO3 (3 mL). The
mixture was stirred at rt.78 After completion of reaction (TLC) then a solution of ethyl acetate :
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NaHCO3 (1:1) was added. The organic phase was separated and washed twice with NaHCO3. The
organic phase was dried over Na2SO4 and concentrate under reduced pressure. The residue was
purified by silica gel column chromatography MeOH : DCM = (5 : 95) to afford 2-3 as a solid
white material, yield = 46 mg (60%). 1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 8.7 Hz, 1H), 7.11
(d, J = 8.9 Hz, 1H), 6.99 (s, 1H), 6.19 (s, 1H), 5.35 – 5.28 (m, 2H), 4.60 (d, J = 12.4 Hz, 1H), 4.35
(d, J = 10.5 Hz, 1H), 4.22 (dd, J = 12.5, 5.0 Hz, 1H), 3.69 (s, 3H), 3.59 (d, J = 7.4 Hz, 1H), 3.55
(s, 3H), 3.44 – 3.35 (m, 4H), 2.84 (dd, J = 4.0, 12.0 Hz, 1H), 2.42 (s, 3H), 2.15 (s, 3H), 2.09 (s,
6H), 2.06 – 2.03 (m, 1H). 13C NMR (100 MHz, CDCl3) δ 170.6, 170.4, 170.1, 161.1, 157.0, 154.4,
152.4, 127.1, 115.9, 115.6, 113.3, 107.5, 100.4, 77.2, 76.2, 74.5, 70.6, 62.6, 61.3, 56.2, 53.0, 50.1,
37.2, 23.8, 20.9, 18.7, 14.2.
4,7-dimethoxy-2-(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid. [MUNANA
(4,7 OMe)]

Compound 2-3 (46 mg, 0.08 mmol) was dissolved in MeOH (7mL) and treated with a
solution of NaOMe (20 µL) and stirred at rt for 1 h. The solution was neutralized with Amberlite®
IR 120 (H+) resin, filtered and concentrate to dryness. The dried compound was treated with NaOH
(0.05 N, 3.0 mL) and reaction was stirred for 4h. After completion of reaction, as monitored by
TLC using DCM:MeOH:NH4OH (8:1.5:0.5), reaction was neutralized with Amberlite® IR 120
(H+) resin, filter, concentrate, then subjected to P-2 gel column to afford MUNANA (4,7 OMe),
yield = 33 mg (84% over two steps). 1H NMR (400 MHz, D2O) δ 7.57 (d, J = 8.8 Hz, 1H), 7.08 –
7.02 (m, 2H), 6.12 (s, 1H), 4.15 (d, J = 10.3 Hz, 1H), 3.98 (t, J = 9.9 Hz, 1H), 3.88 – 3.83 (m, 1H),
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3.80 (d, J = 12.1 Hz, 1H), 3.59 (dd, J = 12.0, 5.8 Hz, 1H), 3.38 – 3.30 (m, 8H), 2.88 (dd, J = 12.7,
3.9 Hz, 1H), 2.31 (s, 3H), 1.98 (s, 3H), 1.84 (t, J = 12.1 Hz, 1H). 13C NMR (100 MHz, D2O) δ
174.1, 172.7, 164.5, 157.3, 156.2, 153.3, 126.1, 117.3, 116.0, 111.5, 107.6, 102.5, 78.1, 78.0, 73.5,
71.3, 62.3, 60.3, 56.7, 49.8, 37.5, 22.2, 17.9. HRMS (ESI): Calculated for C23H29NO11Na
[M+Na] 518.1638; Found 518.1641.
2.5.2

Biological assays

Materials:
Influenza A virus strains: H3N2 (A/Aichi/2/1968), H3N2 (A/Winsconsin/15/2009),
H1N1(A/Netherlands/2629/2009) were obtained from Beiresources (NIAID). S. pneumoniae
(ATCC 6301) were obtained from American Type Culture Collection (ATCC). Enspire plate
reader. 400 µL, 96 well black plates were purchased from Thermo Scientific.
S. pneumoniae bacterial growth:
S. pneumoniae (ATCC 6301) was inoculated in brain heart infusion (BHI) broth that was
augmented with 0.16 g/L of sialic acid to enhance NA production by the bacteria.71 The bacterial
concentration was determined to be 1.2 × 106 CFU/mL using the colony count method. 100 μL of
bacterial solution was lysed using 0.01% SDS, and 20 μL of chloroform was added to it. The
sample was then lysed by vertexing for 30 s and incubating at a temperature of 28 °C for 5 min.
Influenza virus growth:
MDCK (Madin-Darby canine kidney) cells were purchased from ATCC® (CCL-34™,
Manassas, VA) and maintained in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Grand
Island NY) supplemented with 10% Fetal Bovine Serum (FBS Gibco, Grand Island NY). Influenza
A virus strains used in this study were obtained from BEI Resources (Manassas, VA).
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Virus titers of different influenza strains were determined using standard plaque assays in
MDCK cells to quantify the amount of virus.69, 70 MDCK cells were grown to confluency in 6-well
plates. Once confluent, media was removed from the cells and were washed three times with plain
DMEM to remove residual FBS. Virus suspension was serially diluted 10-fold and added to
duplicate wells at 400 µL/well. Virus was adsorbed for 1 h at 37 °C in a 5.0% CO2 incubator. Onehour post-adsorption, virus suspension was removed and Avicel (1.2%, 2.0 mL, FMC Biopolymer)
supplemented with 2 µg/mL TPCK-trypsin (Sigma-Aldrich, St. Louis, MO) was added to each
well. Avicel was prepared as described previously. 77 Plates were incubated for 5 days to allow
for plaque formation. On day 5, the Avicel overlay was removed carefully from each well and the
wells were washed two times with 1X PBS followed by methanol (100%) fixation. Fixed wells
were stained with 0.2% crystal violet and plaques were counted to determine virus titers.
The influence of pH to the activity of virus and S. pneumoniae:
Inactivated A/Aichi/2/1968 H3N2 (sample AC), A/Winsconsin/15/2009 H3N2 (sample
WS), A/Netherlands/2629/2009 H1N1 (sample NL), S. pneumoniae B (sample SB) were incubated
with different buffers (pH = 5.5, pH =7, pH = 8.5, pH = 10) for 30 min. Then the substrate was
added, the fluorescence intensity was detected at 37oC, 360 nm/460 nm for 2 h. Then 1 M, 100 µL
tris solution was added, fluorescence intensity was detected at 37⁰C, 360 nm/460 nm for 10 min.
The influence of DTT to the activity of virus and S. pneumoniae:
Inactivated A/Aichi/2/1968 H3N2 (sample AC), A/Winsconsin/15/2009 H3N2 (sample
WS), A/Netherlands/2629/2009 H1N1 (sample NL), S. pneumoniae B (sample SB) were incubated
with tris or tris + DTT buffer for 5 min. Then MUNANA was added, the fluorescence intensity
was detected at 37oC, 360 nm/460 nm for 2 h. Then 1 M, 100 µL tris solution was added,
fluorescence intensity was detected at 37⁰C, 360 nm/460 nm for 10 min.
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CHAPTER 3 DEVELOPMENT OF POINT-OF-CARE ASSAYS TO MONITOR
MMP-9 AND TNF-α LEVEL IN INFLAMMATORY BOWEL DISEASE

* Most of the work described in this chapter has been submitted in two publications:
1. Dandan Liu, Emilie Viennois, Didier Merlin, and Suri S. Iyer*. Towards Point-of-Care
Assays to Monitor MMP9 and TNF-α Levels in Inflammatory Bowel Disease. Submitted to
ACS Omega. Under review.
2. Dandan Liu, Katie A. Skrada, Didier Merlin, Suri S. Iyer*. Inflammatory Bowel disease
biomarkers. Submitted to Medicinal Research Reviews. Under review.

3.1

Inflammatory Bowel Disease (IBD) Introduction
3.1.1

Classification of IBD

Inflammatory bowel disease (IBD) is characterized by chronic inflammation in
gastrointestinal tract and has no cure.79 There are estimated 6.8 million U.S. adults have been
diagnosed IBD by 2017, which is a large increase since 1999 (2 million)80. Ulcerative colitis (UC)
and Crohn’s disease (CD) are two major subtypes of IBD.
Ulcerative colitis (UC)
UC is a chronic inflammatory disease affects the colon, most commonly afflicting adults
aged 30-40 years old and resulting in disability.81 The factors that lead to UC include: genetic
predisposition, epithelial barrier defects, dysregulated immune responses and environmental
factors. UC is frequently associated with inflammation starting in the rectum and extending to
proximal segments of the colon, mainly the inner side of colon,82 characterized by bloody diarrhea,
tenesmus and abdominal pain.83 Patients with UC can have the following symptoms: urgency,
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incontinence, fatigue, mucus discharge, nocturnal defecations, increased frequency of bowel
movement and abdominal discomfort. UC can be classified into 3 types regarding to the extent of
colonic involvement: proctitis, left-side colitis and extensive colitis.82 (Figure 3.1) Proctitis
involves 30-60% patients, the symptoms could be rectal bleeding, tenesmus and urgency; 16-45%
patients were involved in left-side colitis, the symptoms could be proctitis, diarrhea and abdominal
cramping; 15-35% patients were involved in extensive colitis, the symptoms could be left-side
colitis symptoms plus constitutional symptoms, fatigue and fever. The symptoms can be different
depends on different patients.

A

B

C

Figure 3.1 Classification of UC regarding to the extent of colonic involvement. A.
Proctitis; B. Left-side colitis; C. Extensive colitis. Figure is modified from publisher with
permission.82
Crohn’s disease (CD)
CD is a chronic inflammatory bowel disease affecting any portion of the gastrointestinal
tract from the mouth to the anus, normally afflicting people between 15 and 30 years old. CD is a
relapsing and remitting disease, which only involves a small segment of the gastrointestinal tract,
while it has potential to progress extensively. Factors contribute to CD include immunological,
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genetic and environmental factors. Recently, 163 of rick loci have been identified to trigger IBD,
of which 110 are associated with both CD and UC.84 Environmental factors such as Western diet
are believed contributing to CD. CD is un-continuous disease which can affect all the layers of the
bowel wall. Patients get CD could have symptoms: abdominal pain, fever and clinical signs of
bowel obstruction or diarrhea with passage of blood or mucus.85
3.1.2

Therapeutics of IBD

UC and CD are two main subtypes of IBD, inflammation of UC is limited to the mucosal
layer and the inflammation is continuous, while the inflammation of CD is transmural and it’s not
continuous. Although there are significant differences between UC and CD, most treatment
approaches are effective for both diseases.
Anti-inflammatory drugs
Anti-inflammatory drugs are often the first step to treat IBD, including 5-aminosalicylates
(5-ASA) and corticosteroids.86 Sulfasalazine is a prodrug to treat IBD, which will release active
form 5-ASA through colonic bacteria (Figure 3.2). This drug was developed as a treatment for
rheumatoid arthritis, later was found to effective for IBD patients.87 Due to the poor toleration of
sulfasalazine in up to 30% of patients, a variety of mesalamine derivatives have been developed
to deliver 5-ASA, including azo-linked two molecules of 5-ASA (Olsalazine, Figure 3.3A) and
inert carrier linked 5-ASA (Balsalazide, Figure 3.3B).88, 89 There are also other drugs coated with
protective materials to control (Pentasa) or delay (Asacol, Apriso and Lialda) the delivery of 5ASA.90 5-ASA is effective for treatment of active CD, but not recommended for the maintenance.
For treatment of UC, 5-ASA is effective for the induction and maintenance of remission in mild
to moderate active UC.90
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Figure 3.2 Prodrug sulfasalazine and active form 5-ASA.

Figure 3.3 Structure of Olsalazine and Balsalazide. A. Olsalazine; B. Balsalazide.
Corticosteroids are another kind of anti-inflammation drug, which can bind to a
cytoplasmic receptor and enter the nucleus to introduce a variety of anti-inflammatory effects.91
Common types of corticosteroids used in the treatment of IBD include prednisone,
methylprednisolone,

hydrocortisone

and

budesonide

(Figure

3.4).92

Prednisone

and

methylprednisolone are used to treat moderate to severe cases of IBD93; hydrocortisone is used for
short treatment94; budesonide is used to treat moderate cases of CD95.
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Figure 3.4 Structure of prednisone, methylprednisolone, hydrocortisone and budesonide.
A. Prednisone; B. Methylprednisolone; C. Hydrocortisone; D. Budesonide.
Immunosuppressive agents
Immunosuppressive agents are mainly used when patients were failed with treatment of 5ASA and steroids.96 Immunomodulators include 6-mercaptopurine (6-MP), azathioprine (AZA),
methotrexate (MTX) and cyclosporine (CSA). 6-MP is active form of AZA, (Figure 3.5) both of
them can inhibit lymphocyte proliferation, which might lead to anti-inflammatory effects through
suppression of natural kill cell and T cell activity.97
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Figure 3.5 Structure of 6-mercaptopurine and azathioprine. A. 6-Mercaptopurine B.
Azathioprine.
MTX is a folic acid antagonist, which can inhibit interleukin (IL)-1 and suppress T cell
function. It has been reported that MTX was used for the induction and maintenance of CD98, but
no convincing data for UC. The structure of MTX was shown in Figure 3.6. CSA is a calcineurin
inhibitor, which can form a complex with cyclophilin to block the phosphatase activity of
calcineurin, resulting in the decrease of inflammatory cytokines produced from T cell.99 It is
effective for the induction and maintenance of UC, while no convincing data for treatment of
CD.100

Figure 3.6 The structure of methotrexate.
Biological agents

41
Tumor necrosis factor-alpha (TNF-α) inhibitors, also called biologics, are proved as
biological agents to treat IBD. Human TNF is a family of proteins and receptors that involved in
immune regulation.101 TNF-α is trimer, produced by macrophages or monocytes during acute
inflammation, high concentration of TNF leads to excess inflammation, which is considered as a
proinflammatory cytokine. There are two forms of TNF-α: soluble and transmembrane form, both
forms can perform their biological functions by binding to TNF-α receptors.102 Anti-TNF-α can
neutralize TNF-α, blocking the proinflammation signals.
The first biological agent approved is infliximab to treat moderate to severe IBD in the late
1990s. Infliximab is a chimeric monoclonal IgG1 antibody created by combing mouse and human
TNF, which has a half-life of approximately 14 days.103 This can be used for treatment of CD, UC,
rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.104 Infliximab is administered
intravenously by weight-based dosing, normally dosed every 4-8 weeks after an initial treatment
of 0-6 weeks. The recommended dose for UC and CD patients is 5 mg/kg at 0, 2, 6 weeks, followed
by the maintenance dose of 5 mg/kg every 8 weeks. Data shows infliximab is very effective for
treating IBD, while up to 30% patients show no clinical benefit after induction phase and up to
50% of patients have to discontinue the treatment because of the secondary loss of response or
serious side effect.105-107
Adalimumab is the first fully human monoclonal antibody against TNF-α approved by
FDA in 2002 to treat rheumatoid arthritis. It inhibits TNF-α and its interaction with TNF-α receptor
on the surface of p55 and p75 cell, which has a half-life approximately 2 weeks.108 Adalimumab
was approved to treat moderately to severely active CD and UC in 2007 and 2012 respectively.109
It treats patients who have an inadequate response to conventional therapy or immunosuppressant,
or who are intolerant to or have medical contraindications for such therapies. The recommended
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dose for treating CD and UC is 160 mg on day 1, 80 mg on day 15, followed by a maintenance
dose of 40 mg every two weeks starting at day 29 for less than one year.104
Certolizumab pegol is a monoclonal antibody against TNF-α approved by FDA in 2008 to
treat CD. It is a recombinant antigen-binding fragment (Fab) antibody conjugated to polyethylene,
which is the only PEGylated TNF-α inhibitor without crystallizable fragment (Fc). By conjugating
to polyethylene, the bioavailability, drug stability and plasma half-life were enhanced.110 The
recommended dose to treat CD is 400 mg initially and week 2 and 4, followed by 400 mg every 4
weeks for maintenance if there is response.104
Golimumab is another fully human IgG1 monoclonal antibody against TNF-α, which was
approved by FDA to treat rheumatoid arthritis in 2009. Golimumab is administered by
subcutaneous injection which allows self-administration.111 It was approved to treat moderate to
severe UC in 2013. The recommended dose to treat UC is 200 mg initially and 100 mg at week 2
followed by maintenance dose of 100 mg every 4 weeks.104
Table 3.1 Anti-TNF-α developed to treat IBD.
Drug
Infliximab

Indication

Dose

UC, CD

5 mg/kg at 0, 2, 6 weeks, followed by the maintenance
dose of 5 mg/kg every 8 weeks.

UC, CD
Adalimumab

160 mg on day 1, 80 mg on day 15, followed by a
maintenance dose of 40 mg every two weeks starting at
day 29 for less than one year.

Certolizumab

CD

every 4 weeks for maintenance.

pegol
Golimumab

400 mg initially and week 2 and 4, followed by 400 mg

UC

200 mg initially and 100 mg at week 2 followed by
maintenance dose of 100 mg every 4 weeks.
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3.1.3

Current diagnostics for IBD

Endoscopy
The only way to establish a diagnosis for UC and CD is through the combination of
endoscopy procedure with biopsy of the targeted area. This can accurately differentiate UC from
CD and monitor the disease activity.112
CD can affect any part of gastrointestinal tract; with the most commonly affected area
being the colon. Ileocolonoscopy with collection of multiple biopsy specimens is a wellestablished first line diagnostic in CD.113 The features of endoscopic finding of CD including the
discontinuous chronic and patchy distribution of inflammation with skip lesions.114 During
endoscopic procedures in patients with CD, the inflammation can present in different ways:
erythema, altered vascular pattern, friability, granularity and small discrete superficial and
aphthous ulcers. As the inflammation becomes more severe, deep, serpiginous and linear
ulcerations and a “cobblestone” appearance of the inner wall can develop.115 Anatomical criteria
of severe inflammation in CD includes deep ulcerations across the muscle layer, mucosal
detachments, or ulceration limited to the submucosa but extending to more than one-third of a
defined colonic segment.116 Endoscopy in a patient suffering from UC will show inflammation
that is continuous throughout the colon; while the specific characteristics depend on the severity
of UC. Mild inflammation in UC presents as edema, erythema and abnormal vascularity. Moderate
inflammation can have a “wet sand-paper” appearance, erosions, superficial ulcers and friability.
Severe inflammation in UC appears as confluent ulcerations, worsened friability of epithelium,
and has the potential to develop into spontaneous bleeding.117, 118 The endoscopy might also reveal
rectum sparing or patchy rectal inflammation after treatment.
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In order to obtain a reliable diagnosis, a minimum of two biopsies from five sites around
the colon should be obtained, including rectum and ileum.119,

120

The microscopic features

identified in CD include discontinuous chronic and patchy chronic inflammation, discontinuous
crypt and granulomas. The features above combined with irregular villous architecture can be used
to identify the biopsy samples taken from the ileum.114 UC biopsy samples are characterized by
diffused mucosal granularity, edema and erythema.121 Obtaining a full set of biopsy samples from
the colon can improve the diagnostic yield for both UC and CD, which also might reveal
inflammation not seen in endoscopy alone. Though, this method may be time-consuming and
invasive, the use of endoscopy combined with biopsy sampling has the advantage to diagnose IBD
at an early stage which proves useful for the patient. The differences between UC and CD from
endoscopy are listed in Table 3.2.
Table 3.2 Different endoscopic appearance between UC and CD. Table is taken from
publisher with permission.122
Endoscopic appearance

UC

CD

Distribution

Continuous spread from Any segment of the
the rectum

gastrointestinal tract

Small bowel involvement

Rare

Frequent

Rectal involvement

Almost always

30-50%

Uniform, continuous disease

Always

Infrequent

Longitudinal, polycyclic ulcers

No

Frequent

Cobblestone appearance of ileum

No

Frequent

Normal mucosa within inflamed areas No

Frequent

strictures
Mucosal edema

Frequent

Occasional

Ulceration

Often flat and extensive

Deep

Circumferential inflammation

Frequent

Rare
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Imaging
Numerous studies have been done to investigate less-invasive imaging methods to
potentially diagnose IBD such as magnetic resonance imaging (MRI), computed tomography (CT),
ultrasonography (US), scintigraphy and positron emission tomography (PET).123-125 Imaging plays
an important role in early diagnostics for IBD. It can provide evidence of abnormal bowel in
patients with suspected IBD, particularly CD, and further see where the abnormalities are
distributed in the gastrointestinal tract.126 A meta-analysis, done by Horsthuis, K. et al., discussed
a total of 33 studies to compare the accuracies of US, MRI, CT and scintigraphy imaging to
diagnose patients with suspected IBD.127 The sensitivity and specificity for each method were
respectively: 89.7% and 95.6% for US, 93.0% and 92.8% for MRI, 84.3% and 95.1% for CT,
87.8% and 84.5% scintigraphy.127 CT and MRI are used primarily to view the small intestine. Both
of them can establish the locations and activity of IBD through wall thickness and increased
intravenous contrast enhancement. Meanwhile, imaging with US and scintigraphy can be used to
take images of the colon. MRI and US hold the most accuracy, and furthermore are not involved
in the use of ionizing radiation, which can be harmful to patients over time.128 Considering the
relapsing nature of IBD, frequent reevaluation for most patients is necessary. Therefore, MRI and
US should be considered as a means for initial diagnosis and follow-up evaluation tools for IBD.
Transabdominal ultrasound
Ultrasound, rapidly improving resolution, has become an important tool for diagnostics of
IBD. The diagnosis is based on the assessment of bowel wall diameter and blood flow. The
thickness of the bowel wall can differentiate moderate and severe disease. 129 Pathologic findings
like enlarged lymph nodes, abscesses, stenoses and fistulae can be detected by ultrasound. This
method is also sensitive and specific, but it requires well-trained personnel.
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Biomarkers
Since endoscopy and other methods discussed in the previous section require invasive and
uncomfortable procedures, efforts to diagnose and monitor inflammation have been proposed.
Ideally, non-invasive or minimally invasive self-testing methods are ideal as it would decrease
hospital visits and subsequent discomfort to the patient. Towards this end, there has been
considerable effort directed towards the development of discovering new biomarkers and assays
for diagnosing and monitoring IBD. A biomarker is defined as a substance that can be objectively
measured or evaluated from a tissue or biofluid present in the targeted specimens.130 Several
biomarkers have been identified and proposed as IBD specific biomarkers (Table 3.3). These
biomarkers are discussed in detail in the following sections.
Table 3.3 Biomarkers used for diagnosis of IBD.
Concentration
Biomarker

UC

CD

CRP

20 mg/L

40 mg/L

ESR*

~30 mm/h

Healthy or
remission disease

1 mg/L - 3 mg/L
~20 mm/h

ASCA and p-ANCA
Serological
biomarker

NO

15.3 µM

14.5 µM

13.3 µM

Cytokine (TNF-α,

7.6 pg/ml

12.7 pg/ml

0.02 pg/ml

IL-6, 8, 10, 17, 22)

(TNF-α)

(TNF-α)

(TNF-α)

ST2

56.8 pg/ml

TNFAIP6

5.8 ng/ml

5.6 ng/ml

2.4 ng/ml

NGAL

87 ng/ml

90 ng/ml

60 ng/ml

Calprotectin

1900 µg/g

3200 µg/g

34 µg/g

30.7 pg/ml
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Fecal

S100A12

400 ng/ml

470 ng/ml

70 ng/ml

biomarker

Lactoferrin

1100 µg/g

440 µg/g

1 µg/g

NGAL

6 µg/g

5 µg/g

0.3 µg/g

MPO

100 µg/g

60 µg/g

4 µg/g

MMP-9

6 ng/ml

2 ng/ml

0.6 ng/ml

IAP

20% less

22% less

--

MMP-9

95%

91%

20%

MMP-2

90%

89%

25%

MMP-9/NGAL

90%

86%

3%

Urine
biomarker

A. Serological biomarkers.
1. C-reactive protein (CRP). CRP is considered one of the most important proteins
present in acute inflammation, and was first discovered in 1930 in patients with pneumococcal
pneumonia.131 The production of CRP is amplified in response to most forms of inflammation,
infection, and tissue damage in endothermic animals.132 Human CRP consists of 187 amino acids
and is composed of five identical non-glycosylated polypeptide subunits (Figure 3.7).132 The
correlation between elevated CRP levels and IBD in patients has been investigated through various
studies. Under normal bowel conditions, the concentration of CRP detected in serum is between 1
mg/L – 3 mg/L; while in patients with mild to moderate inflammation, the CRP levels can increase
to 50 – 100 mg/L in 4 to 6 hours.133, 134 A population-based data study showed that at the time of
diagnosis, the median CRP concentration for CD patients is 40 mg/L and in UC patients is 20
mg/L.135 To further examine the correlation of CRP levels to IBD, a study by Solem, C. et al. was
performed to examine the clinical, endoscopic, and histologic activity of both CD and UC. The
results revealed that patients with CD had elevated levels of CRP. They were most associated with
active irritable bowel during colonoscopy (OR, 3; 95% CI, 1-18), as well as histologically severe
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forms of the disease (OR, 10; 95% CI; 1-104). In UC patients, CRP levels were only associated
with histologically severe forms (P = 0.029).136 In more recent years, several studies have been
conducted to compare the levels of CRP in patients treated with the drug infliximab. Louis, E. et
al. compared the CRP levels in CD patients before and after treatment with the drug; 137 while
Iwasa, R. et al. compared them in patients with UC, also before and after treatment.138 The results
indicated that the concentration levels of CRP in patients that positively responded to infliximab,
had significantly decreased.137, 138 CRP accurately reflects the decrease in inflammation when
patients positively respond to the infliximab treatment. These results, in conjunction with the
significant difference between concentration levels in IBD patients and healthy subjects,
demonstrate that CRP is an effective tool in monitoring inflammation flareups in IBD.

Figure 3.7 Molecular structure of CRP. The structure was downloaded from the NIH PDB
database. Molecular structure for CRP (PDB: 1GNH)132 consists of five identical polypeptide
subunits, each represented by a different color.
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2. Erythrocyte sedimentation rate (ESR). ESR determination is a test that can indicate
acute inflammation in patients in a simple and inexpensive way. The test measures the rate of
erythrocytes falling through a vertical column of anticoagulated blood under the influence of
gravity.139, 140 The two main factors that determine ESR are the degree of red blood cell aggregation
and hematocrit, also known as packed cell-volume. Red blood cell aggregation is affected by the
proteins present in blood plasma, which are different based on disease presence.141 In cases of
positive inflammatory response, the erythrocytes will fall at a faster rate and more aggregation will
be present. This positive correlation allows this test to be used to measure the inflammatory activity
that is caused by IBD.142 Turner, D. et al. evaluated the use of ESR to monitor UC in patients, and
also compared it to use of CRP.142 They found the median ESR values for different severity levels
of UC to be as follows: around 17 mm/h in patients in remission from UC, 26 mm/h in mild UC
patients, 37 mm/h in moderate UC patients, and 39 mm/h in severe UC patients (Figure 3.8). A
meta-analysis performed by Holtman, G. et al. showed that the sensitivity and specificity values
for ESR to diagnose IBD were 66% and 84%, respectively.143 While ESR is less accurate than
CRP for the diagnosis of IBD, it still proves to be a useful tool. However, ESR could potentially
be used to monitor inflammation flareups.
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Figure 3.8 Levels of ESR and CRP measured in patients with UC for comparison of
usefulness.142 Samples were taken from UC patients with varying severity of disease. The Kruskal
Wallis test was used to compare test results across the levels of disease activity.

3. ASCA, p-ANCA, and other antibody markers. Anti-Saccharomyces cerevisiae
antibodies (ASCA) and perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) have been
characterized as serological markers for inflammation for many years. They were first discovered
in UC patients in 1990.144 ASCAs were detected in the serum of 50 – 60% of patients with CD;
and had diagnostic values for sensitivity and specificity of 67% and 92%, respectively.145 PANCAs were detected in the serum of 60 – 70% of UC patients, with only 15% of CD patients
presenting with antibodies.146 Most studies used enzyme-linked immunosorbent assay (ELISA) to
detect ASCA and p-ANCA; a sample was considered positive when a concentration of >15 U/ml
was detected. Indirect immunofluorescence assay (IIF) was also used to measure p-ANCA to
differentially diagnose patients with CD or UC; a sample was considered positive when >24
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U/ml.147 Mokhtarifar, A. et al. tested patients at a one-year follow up exam, for ASCAs and pANCAs to re-examine their diagnoses of UC or CD.147 The results showed that ASCA+/p-ANCAcan diagnose CD with a sensitivity of 67% and specificity of 78%; while, ASCA-/p-ANCA+ can
diagnose UC with a sensitivity of 78% and specificity of 67%, respectively. Other antibody
markers have shown positive correlations with IBD patients; these include anti-outer-membrane
porin C (OmpC) and anti-Cbir1 antibodies. These have been positively detected in around 50 –
55% of CD patients, 5% - 10% of UC patients, and 5 – 8% of healthy subjects.148-151 Combining
multiple antibodies in a single test is preferred as it decreases false positives and negatives. In one
study, a group of four genetic markers (ATG16L1, NKX2-3, ECM1, and STAT3), five
inflammatory markers (CRP, SAA, ICAM-1, VCAM-1, and VEGF), and two serological markers
(A4-Fla2 and FlaX) were selected for the diagnosis of IBD in combination with a six serological
marker panel (ASCA-IgA, ASCA-IgG, ANCA, pANCA, OmpC, CBir1).152 The results of the
combination test were then compared to the results from the six serological marker panel for
comparison.152 The outcome showed that with this extended marker panel, discrimination area
under the curve of IBD versus non-IBD increased to 0.87 (95% CI, -0.4 – 0.4) from 0.80 (95% CI,
-0.5 – 0.5; P < 0.001). In addition, the discrimination area under the curve for differential diagnosis
of UC from CD increased to 0.93 (95% CI, -0.4 – 0.4) from 0.78 (95% CI, -0.6 -0.6; P < 0.001).
4. Nitric oxide (NO). NO is a stable, yet mildly reactive free radical and gaseous signaling
molecule present in mammalian cells, that plays a vital role in the regulation of various
physiological and pathophysiological responses.153 Some of these processes include vascular
homeostasis, neurotransmission of the central nervous system and in peripheral nerves, as well as
hemostasis and host defense.153,

154

The possibility of NO working as a mediator in the

inflammatory processes of IBD has fuelled many studies over the years.155 Several manifestations
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of IBD have been found to directly or indirectly correspond with NO, such as vasodilation and
increased vascular permeability. A study done by Avdagić, N. et al. investigated the potential of
serum NO as biomarker to diagnose UC and CD.156 The result showed the level of serum NO was
statistically different between UC patients, CD patients, and healthy controls. The median NO
concentrations in UC patients, CD patients, and healthy controls were 15.3 µM, 14.5 µM, and 13.3
µM, respectively. With a cut-off of 17.4 µM, the sensitivity and specificity of NO to differentiate
between active and inactive UC patients were both 100%. And with a cut-off of 14 µM, the
sensitivity and specificity of NO to differentiate between active and inactive CD patients were
88% and 69%, respectively. These results indicate that serum NO could be a potential biomarker
for IBD.
5. Cytokines. Tumor necrosis factor- α (TNF-α) was first identified in the 1970’s as a
soluble cytokine capable of significant cytotoxic activity against tumor cell lines, and is released
upon activation of the immune system.157 TNF-α is important for pro-inflammatory activity and
have vital roles in the pathogenesis of chronic inflammatory diseases. The effects of TNF-α are
carried out when this trimer (Figure 3.9) protein binds to and forms clusters with high-affinity
receptors TNF-R1 and TNF-R2 on cell membranes.158, 159 Once TNF-α is bound to its receptor,
depending on the type of cell membrane, it will play part in numerous physiological and
pathological responses.159 TNF-α can be found in elevated levels in the GI tract of colitis patients,
and has a major role in mucosal inflammation.159, 160 A study conducted by Komatsu, M. et al.
tested the concentrations of TNF- α using highly sensitive immuno-PCR, which resulted in
concentrations that were significantly different between IBD patients and healthy controls.161
Results for median TNF-α concentrations are as follows: 7.6 pg/ml in patients with UC, 12.7 pg/ml
in patients with CD patients, and 0.02 pg/ml in healthy controls. This study was the first to result
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in strikingly higher concentrations of TNF- α in IBD patients than in healthy controls; most likely
due to the use of immune-PCR assay in comparison to conventional serum assay methods used in
the past. TNF- α in the inflamed mucosa of IBD patients need further exploration but should be
considered as a potential biomarker for its strong correlation to inflammation in the body.

A

B

E-F loop

Figure 3.9 Overall structure of human TNF-α and its monomer binding with infliximab.
Structures downloaded from NIH PDB database. A. Overall structure of TNF-α (PDB: 1NTF).162
It is a trimer, each monomer shown in different colors (green, cyan, purple). The E-F loop is shown
in red, which plays a central role in antibody-antigen binding. B. TNF-α monomer binding with
infliximab Fab (PDB: 4G3Y).163 Infliximab Fab heavy chain is shown in orange, while the light
chain is shown in dark blue. The TNF-α monomer is shown in green and the E-F loop is shown in
red. One trimer of TNF-α can bind at most three infliximab molecules.163

There are several other cytokines indicate the inflammation in IBD, such as interleukin-6
(IL-6), IL-8, IL-10, IL-17 and IL-22.164-166 ILs are a group of cytokines first discovered express in
leukocytes and there are more than 50 ILs in human.167 IL-10 is a dimer, each monomer consists
of six helices . Each IL-10 molecule can bind with two molecules of IL-10 receptor to induce
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cellular responses.168 IL-10 is an immunoregulatory cytokine inhibiting the production of
proinflammatory cytokines, such as TNF-α, IL-1, IL-6 and IL-12.169-171 It is also a growth and
differentiation factor for B cells, thymocytes and mast cells, and it plays an important role in
preventing inflammatory and autoimmune pathologies.172,

173

IL-10 is mainly secreted by

monocytes and release to serum and stool.174 Kühn, R. et al. found that IL-10 deficient mice
develop chronic intestinal inflammation.175 Therefore, IL-10 knocked mice model normally are
used for colitis study. Mitsuyama, K. et al. compared the concentration of IL-10 in active UC, CD
patients and healthy subjects with ELISA.164 The result showed the concentration of IL-10
increased in active UC and CD patients, which might be a helpful biomarker for IBD.
6. ST2. Suppression of tumorigenicity 2 (ST2) was first discovered in 1989, and belongs
to interleukin 1 receptor family.176 ST2 is mainly expressed in cardiac fibroblasts and
cardiomyocytes in response to injury or stress. However, non-myocardial sources of ST2 are
known, and are associated in inflammatory and immune processes.177 Overexpression of ST2 has
been positively identified in correlation with UC, and Boga, S. et al. set out to investigate the
endoscopic, clinical, and histopathological assessment for serum ST2 levels in patients with UC
and CD, in comparison to healthy controls.178 A total of 143 IBD patients participated in this study,
83 UC subjects and 60 CD subjects, along with 50 healthy controls. ST2 serum levels were
detected using ELISA testing; and endoscopic disease activity was measured by the CD activity
index (CDAI) and the clinical colitis activity index (CCAI). The median concentrations of serum
ST2 in UC patients, CD patients, and healthy controls were 54 pg/ml, 64 pg/ml, and 31 pg/ml
respectively. Which showed a significant increase in IBD patients compared to healthy controls.
In addition, this study found that the serum ST2 levels were positively correlated with endoscopic
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activity for both UC and CD patients.178 The results of these studies indicate that ST2 serum is a
useful biomarker to measure the clinical course of IBD patients.
7. TNFAIP6. Tumor necrosis factor alpha-induced protein 6 (TNFAIP6), also known as
TSG-6, is a protein that is secreted during times of inflammation in various cell types.179 It has
been suggested that TNFAIP6 plays a vital role in extracellular matrix formation or developmental
properties.180 High levels of TNFAIP6 have been detected in mucosal samples taken from patients
with IBD; specifically in mucosal smooth muscle cells.179 However, there has not been much
investigation into the link between serum levels of TNFAIP6 and disease activity in patients with
IBD. The serum levels for TNFAIP6 and CRP were tested against the disease activity in IBD using
the CD Activity Index in CD patients, and Mayo Score in UC patients. Results showed that the
correlation coefficients (r) were comparable for the CD activity index with values of 0.378 and
0.39 for TNFAIP6 and CRP, respectively; and for the UC Mayo Score, TNFAIP6 serum had a
higher correlation value than that of CRP with values of 0.65 and 0.51, respectively.181 While CRP
shows higher accuracy for measurement, TNFAIP6 still proves useful for the monitoring of IBD
disease activity and should be considered in further studies as a potential biomarker for diagnosing
IBD.
B. Fecal biomarkers.

56

Figure 3.10 The fecal biomarkers secretion of IBD. The inflammation in the gut mucosa
leads to enhanced migration of innate immune cells, such as monocytes, macrophages and
neutrophils to the affected mucosa. These cells secrete inflammatory mediators, such as
calprotectin, lactoferrin, MMP9 et al. actively and the mediators are released to gut lumen, which
can be detected from feces. Figure is modified from publisher with permission.182
1. Calprotectin. Calprotectin is a calcium-binding protein that was first isolated from
granulocytes back in 1980. It is mainly found in the cytosol of neutrophils, but can also be detected
in monocytes and reactive macrophages in lower quantities.183 Calprotectin possesses
antimicrobial and antiproliferative properties and belongs to the S100 family of proteins, which
are responsive to acute and chronic inflammation, as well as various malignancies.184 Calprotectin
is a heterodimeric protein composed of subunits S100A8 and S100A9 (Figure 3.11).185 During
inflammation, calprotectin can be detected in elevated levels in blood plasma, cerebrospinal fluid,
synovial fluid, urine, and feces.185 The concentration levels of calprotectin present in the feces of
subjects is around six times greater than those found in plasma.186 The calprotectin concentration
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in healthy subjects is found to be around ~ 34 µg/g in feces. For patients with CD, the concentration
increases significantly to ~ 3200 µg/g; and for UC patients it is around ~1900 µg/g. 187 Due to the
large difference in concentration of calprotectin between healthy patients and those with CD or
UC, For these reasons, numerous studies have used fecal calprotectin as an indicator for
inflammation in patients.184, 186, 188, 189 A meta-analysis performed by Freeman, K. et al. examined
the use of fecal calprotectin to diagnose IBD, through various methods of measurement: ELISA,
fluorescence enzyme immunoassay (FEIA), and Quantum-Blue point-of-care test.190 It showed
that the sensitivity from different assays ranged from 85% to 94%, and the specificity ranged from
67% to 88%. Calprotectin concentration can also be used to measure effect of interventions.
Sipponen, T. et al. studied the effect of anti-TNF-α treatment on calprotectin levels, and found that
the median fecal concentration in CD patients decreased from 1200 µg/g to 130 µg/g through
treatment .191 To summarize, fecal calprotectin is a very useful biomarker for the diagnosis and
monitoring of inflammation in IBD patients.
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Figure 3.11 Overall molecular structure of calprotectin heterotetramer. The structure
downloaded from the NIH PDB database. The heterotetramer structure of calprotectin (PDB:
1XK4)189 is composed of two heterodimer protein subunits: S100A8 and S100A9, forming the total
formation structure (S100A8/S100A9)2. S100A8 subunit is shown in pink color, S100A9 is shown
in teal color. Calcium ions bound to each EF-hand formation are shown as yellow spheres.

2. S100A12. S100A12, also known as Calgranulin C, is a calcium-binding proinflammatory protein that belongs to the S100 protein family.192 S100A12 binds to cell surface
receptor RAGE on inflammatory cells, which results in the activation of several intracellular signal
cascades.193 This ligation specifically activates nuclear factor (NF)- B transduction pathway and
MAP-kinase pathway—leading to the production of proinflammatory cytokines, such as tumor
necrosis factor (TNF)-α and IL-1b.194, 195 Several reports elaborate S100A12 and its role in various
inflammatory diseases, these include rheumatoid and psoriatic arthritis193, cystic fibrosis196,
various respiratory disorders197, and IBD.192 Since S100A12 is secreted by activated human
neutrophils, which play a vital role in the inflammatory processes of IBD, the levels of serum
S100A12 in IBD patients have been investigated. A study performed by Foell, D. et al. determined
the tissue expression of S100A12 in IBD patients.198 The results of the study show that
concentration levels for S100A12 were around 470 ng/ml in patients with active CD, and 400
ng/ml in patients with active UC; compared to 75 ng/ml in healthy controls.198 Since S100A12 has
been positively identified in the feces of IBD patients, this biomarker could potentially be used as
an effective non-invasive self-testing method.
3. Lactoferrin. Lactoferrin (LTF) is an iron-binding glycoprotein whose function is to
transport iron in blood serum, but also plays an important role in first line immune defense.199 This
protein can be found in most mammalian exocrine secretions, such as tears, saliva, gastrointestinal
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fluids, or breastmilk; or in the secondary granules of neutrophils. LTF levels are shown to increase
significantly in the biological fluids of patients who suffer from various inflammatory diseases.200
It has been of interest to measure IBD activity in patients through the use of fecal LTF sampling.
Kane, S. V. et al. compared the concentration levels of fecal lactoferrin in patients with IBD to
healthy controls using ELISA.201 In healthy subjects, the concentration was found to be around
~1 µg/g, in CD patients it increases to ~440 µg/g, and in UC patients it is ~1100 µg/g.201 The
sensitivity and specificity of fecal LTF to diagnose UC in patients were 81% and 82%,
respectively; while the sensitivity and specificity to diagnose CD were 82% and 0.71%,
respectively.141
4. Lipocalin-2/NGAL. Neutrophil gelatinase-associated lipocalin (NGAL), also known as
lipocalin-2, is a glycoprotein originally isolated from neutrophils that can be found in monomeric
and homodimeric forms, as well as in a NGAL-gelatinase complex.202 The presence of NGAL is
expressed in elevated levels in chronic and acute inflammation and a wide array of benign and
malignant diseases effecting various organ including digestive, respiratory, endocrine, and
reproductive organs.203, 204 High NGAL expression has been positively identified in IBD patients
with inflamed colonic epithelium.203 In one study with a limited number of patients, i.e. 21 patients
with IBD and 23 healthy patients, the median concentration of NGAL present in UC patients was
6 (4 – 15) µg/g, and in CD patients at 5 (2 – 8) µg/g in contrast to healthy subjects expressed lower
concentrations at around 0.3 (0.1 – 0.4) µg/g.205 The sensitivity and specificity to diagnose active
IBD from the subjects were 94.7% and 95.7%, respectively. Based on these studies, NGAL is also
considered as a potential biomarker for IBD.
5. Myeloperoxidase (MPO). MPO is an enzyme found in the azurophil granules of
neutrophils, and is used as a microbicidal agent that can attack foreign materials.206 The MPO
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concentration is directly proportional to the number of neutrophils.207 Since neutrophils play a vital
role in the inflammatory processes of IBD and are directly correlated to MPO, studies to correlate
inflammation to MPO levels were undertaken.208 It was demonstrated that median concentration
of MPO was < 4, 100 and 60 µg/g in healthy, UC and CD patients, respectively. These results
show a significant difference in the MPO levels of IBD patients compared to healthy subjects,
which indicates the potential of MPO as a biomarker for IBD.
6. Matrix metalloproteinases (MMPs). MMPs are a group of zinc-dependent
endopeptidases with a conserved catalytic domain, and a Zn2+ present at the active site; collectively
termed matrixins.209, 210 MMP-9 along with MMP-1, 2, and 3, have been detected in significantly
high levels in colonic biopsies from IBD patients.211 MMP-9, also known as gelatinase B, has three
repeat domains of type II fibronectin domain into the catalytic domain, which is used for binding
to gelatin, collagens, or laminin (Figure 3.12). Baugh, M. D. et al. explored the expression of
multiple MMP-1, MMP-2, MMP-3, and MMP-9 in patients with IBD.212 A recent study evaluated
the diagnostic value of fecal MMP-9 in different types of IBD using ELISA.211 The results showed
that the median concentration of fecal MMP-9 was 1.5 ng/ml in active CD patients, compared with
0.6 ng/ml in inactive CD patients; and 6.2 ng/ml in active UC patients, compared to 0.7 ng/ml in
inactive UC patients. Fecal MMP-9 did not show a strong correlation with any of the disease
activity indicative of CD. However, it did show a strong association with the clinical and
endoscopic activities of UC. For UC patients with positive endoscopic activity, the sensitivity and
specificity of fecal MMP-9 to diagnose UC were 96% and 75%, respectively.
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Catalytic domain
Propeptide

FnII domain 1

FnII domain 3

FnII domain 2

Figure 3.12 Overall structure of proMMP-9. Structure downloaded from the NIH PDB
database. ProMMP9 (PDB: 1L6J)213 consists of 5 domains: propeptide (yellow color), catalytic
domain (orange color) and 3 Fibronectin type II (FnII) domains (green, blue and cyan colors). Zn
atoms were shown in black color and Ca atoms were shown in red color. ProMMP9 is enzymatic
inactive and it can be activated by cleavage of propeptide. Zn is binding with catalytic domain,
which is important for MMP9 enzymatic activity.
7. Intestinal alkaline phosphatase (IAP). IAP belongs to a superfamily of
metalloenzymes and is considered a crucial mucosal defense factor that works to maintain gut
homeostasis.214 While this enzyme is rarely found in the stomach of healthy subjects, it is present
in the apical microvilli of the brush border of enterocytes found in the intestine. It is secreted
apically and basolaterally by the enterocytes, and is expressed in the intestinal lumen, as well as
the bloodstream, in response to inflammation.214, 215 Another study performed by Park, Y. S. et al.
evaluated the expression of IAP in the disease course of CD patients.216 A total of 32 CD patients
participated in the study and were monitored over the course of 14 months after biopsy sampling.
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ELISA tests detected IAP concentrations in the intestinal mucosa; and samples were taken from
inflamed and non-inflamed areas of the colon. Results showed that 31.3% of patients had lower
IAP expression in inflamed mucosa compared to non-inflamed mucosa; the median value of IAP
in inflamed mucosa was ~ 43 ng/ml, compared to 26 ng/ml in non-inflamed mucosa. Of the patients
with this disparity in IAP levels, 90% experienced clinical recurrences of CD. This suggests that
the concentration of IAP in the intestinal mucosa of CD patients may be associated with clinical
recurrences of the disease, proving its usefulness as a potential biomarker for monitoring IBD.
Establishing the limit of detection and range of detection of the two biomarkers in
IL10-/- mice, and development of assays to detect inflammatory biomarkers in our research
group
We were interested in developing assays that could potentially be used in POCTs to
monitor inflammation in IBD. Our long-term goal is to decrease the number of hospital visits and
uncomfortable endoscopies for patients who have been diagnosed with IBD. If POCTs were
available to monitor inflammation, IBD patients could use it in the privacy of their homes, test
frequently and transmit the results to their physician. The physician could use the results to
prescribe drugs or modify the drug dose, thereby reducing morbidity.
We first describe our efforts to establish the Limit of Detection (LOD) and range of
detection of the two biomarkers (MMP-9 and TNF-α) in IL10-/- mice, followed by our efforts on
assay development using mesoporous silica nanoparticles. MMP-9 level in mice fecal samples
were detected by InnoZyme™ Gelatinase (MMP-2/MMP-9) Activity Assay kit (Catalog#:
CBA003, Sigma). TNF-α level in mice serum samples were detected by TNF alpha Mouse ELISA
Kit, High Sensitivity (Catalog#: BMS607HS, Thermo Fisher Scientific). Afterwards, we
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developed assays to detect fecal MMP-9 and serum TNF-α using “cap and release” mesoporous
silica nanoparticles (MSNs).
3.2

Mesoporous Silica Nanoparticles (MSNs) Introduction
3.2.1

A primer on MSN

MSNs have been drawn great attention as drug delivery system recent years. Due to its
unique propensities, such as large loading capacity217, 218, homogenous porosity217, inertness and
easy functionalization, it has been widely used in diagnostics219, 220, drug delivery221, 222, sensing223,
224

and bioimaging225. There are two methods widely used to synthesize MSNs, one is solution-

based synthesis, another is aerosol-based evaporation-induced self-assembly (EISA).226
Solution-based synthesis
Cetyltrimethylammonium bromide (CTAB) is most commonly used template molecule to
synthesize MSNs. When it presents in concentrations greater than the critical micelle concentration
in aqueous solution, it will form spherical micelles by self-assemble. After this, tetraethyl
orthosilicate (TEOS) was added, it will form surface in hydrophilic interface of the micelles by
electrostatic interaction. Followed by removing the template by calcination or acid extraction,
MSNs will be produced (Figure 3.13). The dimensions of MSNs synthesized by this method range
from 25 nm to 250 nm.227

Figure 3.13 Synthesis of MSN. Figure is taken from publisher with permission.228
EISA
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EISA begins with soluble silica and surfactant in ethanol/water solution with low
concentration. As the solvent evaporate, the concentration of surfactant increases gradually,
leading to self-assembly of silica/surfactant micelles and further form liquid-crystalline
mesophases. The size of MSN synthesized by this method also has the particle size range from 25
nm to 250 nm.
3.2.2

Classification of MSN

Different types of MSN have been developed and used for drug delivery system, including
Mobile Crystalline Material (MCM) system, Santa Barbara Amorphous (SBA) system, Korea
Advanced Institute of Science and Technology (KIT) system and hollow MSNs.229-231
Table 3.4 Different types of MSNs.
MSN types

Pore size (nm)

MCM

1.5 – 8

SBA

2- 15

KIT

9

Hollow

100 - 150

MCM system including MCM-41, MCM-48, MCM-50, and MCM-41 is most commonly
used for drug delivery. MCM-41 has a 2D hexagonal structure, characterized by a large surface
area, a unidirectional pore system composed of a regular hexagonal array of tubes with high
thermal stability.232 Pore size of MCM-41 is around 1.5-8 nm.232 MCM-48 has a 3D cubic structure,
which has a larger surface area than MCM-41. The pore size of MCM-48 is around 2-5 nm. MCM50 is characterized by 1D lamellar structure, which is formed by sheets or bilayers of surfactant
molecules with hydrophilic head groups pointing towards silicate.233
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SBA system, synthesized by polymer templates, mainly include SBA-1, SBA-2, SBA-3,
SBA-11, SBA-12, SBA-15 and SBA-16. SBA-1, 2 and 3 were synthesized by cationic
surfactants234, 235, while SBA-11, 12, 15 and 16 were synthesized in acidic condition with nonionic surfactants236,

237

. The structure of SBA-15, similar to MCM-41, has a 2D hexagonal

mesoporous structure, but with a thicker pore wall and larger pore size.238
KIT system including KIT-5 and KIT-6, KIT-5 has 1D cubic structure and KIT-6 has 3D
network consisting of two interwoven nanochannels. TUD-1 is characterized by a foam-like
mesoporous structure, which is disordered 3D network.230
Hollow MSNs have a larger pore size, around 100-150 nm, which has 3-15 times higher
loading capacity than MCM.239 As a result, lower amount of hollow MSNs are needed to achieve
the desired cargos than MCM. Therefore, hollow MSNs have been widely used to deliver
therapeutic drug recently.240
3.2.3

Application of MSN to detect IBD

Patients with IBD require long term management and frequent follow-up with their
physician. The gold standard to detect and manage IBD is endoscopic evaluation to monitor
inflammation and the procedure may be combined with biopsy to determine if there is cancerous
growth.241 However, this method is invasive and patients often experience pain and discomfort
during these procedures, highlighting the need for a non-invasive and cost-effective technique to
monitor inflammation. The concentration of fecal calprotectin is correlated with both endoscopic
and histological inflammation scores in IBD.241 Although a non-invasive procedure, the current
assay for fecal calprotectin is not user-friendly and perceived as expensive for POC diagnosis.
Here, we have explored the value of matrix metallopeptidase 9 (MMP-9) and tumor necrosis factor
alpha (TNF-α) as alternative biomarkers. The level of MMP-9, a 92 kDa gelatinase, increases
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during inflammation in IBD patients and is released into urine, stool and blood.211, 212 TNF-α also
increases during inflammation in serum.242 The main goal of this study is to explore the correlation
between concentrations of MMP-9, TNF-α and severity of colitis in IL10-/- mouse model, with a
view to designing an effective tool for POC diagnostics for human IBD, since IL10-/- mouse model
has similar condition with human IBD.
Here, we used MSNs to rapidly detect MMP-9 and TNF-α. First, we developed an assay
using an MMP-9 substrate to cap MSNs; when MMP-9 in a sample is introduced, the enzyme
opens the cap via cleavage of the substrate and the contents, i.e. the dye is released. A second assay
was also developed, where TNF-α antibody is used to cap MSN; when samples containing TNFα antigen is introduced, the antigen binds strongly to the antibody to open the cap and release the
dyes.
3.3

Experiment Design
3.3.1

MMP-9 detection

We choose MCM-41 that is commercially available as the MSN because this MSN is well
characterized and has been used in several studies217, 218, 243. For the cap, we chose an MMP-9
specific substrate, because MMP-9 specifically recognizes and cleaves the peptide sequence
PLGMWSR244.

Accordingly,

to

fully

cap

the

pore

of

MSN,

a

peptide,

PLGMWSRPLGMWSRPLGMWSR-pentynoic acid (peptide P), containing three repeats of the
MMP-9 substrate, PLGMWSR, and pentynoic acid at the end for pore capping was designed243.
This peptide P contains an alkyl group, which can be attached on the surface of MSN by click
reaction with azide group on the MSN. We choose three repeating units of the peptide to ensure
minimal leakage of the dyes from the pores of MSN. In this system, the alkyne group of pentynoic
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acid reacts with the azide group modified on the surface of MSN and the cargo within the pore is
released after peptide cleavage (Figure 3.14)

Peptide P

MMP-9

MSN-N3
MSN-P
Rhodamine b

Figure 3.14 Experimental design of MMP-9 substrate capped MSN. The external surface
of MSN was modified by azide group, rhodamine b was loaded and capped using the peptide
substrate. Introduction of MMP-9 releases the dye by cleaving the substrate.
3.3.2

TNF-α detection

First, the MSN surface was modified with (3-Aminopropyl) triethoxysilane (APTES) to
generate MSN-NH2 that was positively charged in PBS buffer. MSN-NH2 was subsequently
suspended in fluorescein solution to load the dye via diffusion. Next, negatively charged TNF-α
antibody was added for capping of MSN-NH2 via electrostatic interactions. The presented TNFα antigen could bind the antibody, open the gate and release the dye, which was detectable via
fluorescence. (Figure 3.15)
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TNF-α
antibody

MSN-NH2

TNF-α

MSN-Ab
Fluorescein

Figure 3.15 Experimental design of TNF-α antibody capped MSN. MSN was modified by
(3-aminopropyl) triethoxysilane (APTES) to afford MSN-NH2. After loading the dye, negatively
charged TNF-α antibody was used to cap the nanoparticles. Introduction of TNF-α antigen results
in tight binding of the antibody to the antigen and opens to cap to release the dye.
3.4

Results and Discussions
3.4.1

Association between MMP-9 and TNF-α level with IBD severity.

MMP-9 detection with IL10-/- mouse model. First, we established the concentration of
MMP-9 to monitor inflammation in wild-type and IL10-/- mice. IL10-/- mouse model is a genetic
model that spontaneously develop colitis with age.245 Mice fecal samples of wild-type (mice
without colitis) and IL10-/- (with colitis) groups were detected with InnoZyme™ Gelatinase
(MMP-2/MMP-9) Activity Assay kit. The results showed MMP-9 level in IL10-/- mice was
significantly higher than that in the wild-type group (Figure 3.16). The mean MMP-9 levels were
18 ± 3 ng/ml (n = 3) in wild type mice and 31 ± 8 ng/ml (n = 3, P < 0.05) in IL10-/- mice. Next,
we compared MMP-9 levels among IL10-/- mice of different ages, before (4 weeks-old) and after
mice developed colitis (14 weeks-old) with the assay kit. The severity of colitis increased with
ages of IL10-/- mice.245 The mean MMP-9 levels were 12 ± 20 ng/ml (n = 8) and 28 ± 22 ng/ml
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(n = 8, P < 0.005) in 4 week old mice and 14 week old mice, respectively, which shows that MMP9 levels were higher with increasing severity of colitis (Figure 3.17). Fecal samples of IL10-/mice treated with anti-TNF-α antibody, which is commonly used to treat IBD246, 247, and nontreated IL10-/- mice that developed colitis were further compared (Figure 3.18). Non-treated mice
had higher levels (28 ± 22 ng/ml, n = 8) of MMP-9 than treated mice (7 ± 6 ng/ml, n = 8, P < 0.05),
confirming that the MMP-9 concentration is correlated to severity of colitis. Taken together, these
studies confirm that POC diagnostics that monitor MMP-9 levels could be used to monitor
inflammation associated with IBD.

P < 0.05
[MMP9] (ng/ml)

40
30
20
10
0

0.6

0.8

Wild mice

1.0

1.2

1.4

IL10-/- mice

Figure 3.16 The difference of fecal MMP-9 between wild mice (black column) and IL10-/mice (red column) at 14 weeks-old, detected by fluorescence. The mean concentration of fecal
MMP-9 in IL10-/- mice (31 ± 8 ng/ml, n = 3) is significantly higher than wild mice (18 ± 3 ng/ml,
n = 3, P < 0.05). All experiments were performed in triplicate.
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Figure 3.17 The difference of fecal MMP-9 in different ages of IL10-/- mice. The mean
concentration of fecal MMP-9 was detected by fluorescence at week 4 (12 ± 20 ng/ml, n = 8) and
week 14 (28 ± 22 ng/ml, n = 8, P < 0.005). As age progresses, the concentration of fecal MMP-9
is higher. All experiments were performed in triplicate.
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Figure 3.18 The difference of fecal MMP-9 in anti-TNF-α treated and non-treated IL10-/mice. The mean concentration of fecal MMP-9 in non-treated mice (red box, 28 ± 22 ng/ml, n =
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8) is higher than in anti-TNF-α-treated mice (black box, 7 ± 6 ng/ml, n = 8, P < 0.05). All
experiments were performed in triplicate.
TNF-α detection with IL10-/- mouse model. We also established the serum TNF-α
content increases with severity of IBD by comparing groups of mice of different ages, along with
groups of anti-TNF-α-treated and non-treated IL10-/- mice. The differences in TNF-α levels in
mice serum from different age groups (week 4 and week 14) are presented in Figure 3.19 (Mean
TNF-α concentration in week 4 vs week 14 = 1.0 ± 0.9 vs 4.7 ± 2.6 pg/ml, n = 7 vs 7, P < 0.01).
Our data clearly revealed increasing TNF-α concentration in serum with severity of colitis.
Differences in TNF-α levels in serum between anti-TNF-α treated and non-treated mice are
presented in Figure 3.20 (Mean TNF-α concentration in non-treated vs treated = 4.7 ± 2.6 vs 1.3
± 1.5 pg/ml, n = 7 vs 7, P < 0.05). The mean serum TNF-α content was significantly higher in nontreated than treated mice in our experiments. Based on these findings, we propose that colitis
conditions may be effectively evaluated by monitoring the serum TNF-α concentration.
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Figure 3.19 The serum TNF-α concentration in different age of IL10-/- mice. The mean
concentration of serum TNF-α was detected by purchased ELISA assay kit at week 4 (1.0 ± 0.9
pg/ml, n = 7) and week 14 (4.7 ± 2.6 pg/ml, n = 7, P < 0.01). As age progresses, the concentration
of serum TNF-α is higher. All experiments were performed in triplicate.
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Figure 3.20 TNF-α levels between anti-TNF-α treated and non-treated mice. The result
shows that the concentration of serum TNF-α in non-treated mice (red box, 4.7 ± 2.6 pg/ml, n =
7) is significantly higher than treated mice (black box, 1.3 ± 1.5 pg/ml, n = 7, P < 0.05). All
experiments were performed in triplicate.
3.4.2

“Cap and release” MSN to detect MMP-9 and TNF-α.

After establishing the limit and range of detection of the two biomarkers, MMP-9 and TNFα in wild type healthy and IL10-/- mice, we attempted to develop POC diagnostics to monitor
inflammation associated with IBD.
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MMP-9 detection. We examined rhodamine b release for MMP-9 substrate capped MSNP. Briefly, 1 mg MSN-P was suspended in 1 ml PBS buffer and divided into two fractions, each
containing 500 µg MSN-P. One fraction was treated with 50 µl PBS buffer as control and another
with 50 µl (0.1 mg/ml) MMP-9. Both suspensions were incubated at 37℃ and release of dye were
detected at different time-points. The results are shown in Figure 3.21. Remarkable release of
rhodamine b was observed in the presence of MMP-9 within minutes, while release was minimal
in its absence. This demonstrates that the substrate cap was cleaved by MMP-9 to release the dye
trapped in the pores of MSNs. To determine the limit of detection for MMP-9, we employed
different concentrations for the release study (Figure 3.22). The limit of detection was measured
as ~0.625 µg (1.1 µg/ml).
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Figure 3.21 Detection of MMP-9 using dye loaded MSNs. In the presence (red line, filled
circles) of fecal MMP-9, dye release was significantly increased compared to the absence (black
line, filled squares) of MMP-9. All experiments were performed in triplicate.
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Figure 3.22 The limit of detection for MMP-9. Different concentration of MMP-9 were
used to detect the release in different time points (Control was shown in black line, filled squares;
0.625 µg MMP-9 was shown in red line, filled circles; 1.25 µg MMP-9 was shown in blue line,
filled up triangles; 2.5 µg MMP-9 was shown in purple line, filled down triangles; 5 µg MMP-9
was shown in green line, filled diamonds). As the concentration of MMP-9 increases, the released
dye will increase. The limit of detection was measured as ~0.625 µg (1.1 µg/ml). All experiments
were performed in triplicate.
TNF-α detection. We also examined the fluorescein release for TNF-α antibody capped
MSNs, MSN-Ab. 1 ml suspended MSN-Ab in PBS was divided into two fractions, each
containing 500 µl MSN-Ab. One fraction was treated with 12 µl PBS buffer as the control group
and the other with 12 µl of 3 µg TNF-α antigen as the experimental group. Fluorescein release
from both groups was detected at different time-points. Significant release was observed in the
presence of TNF-α, while release was relatively small in its absence (Figure 3.23). Different
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concentrations of TNF-α were used for the release study to measure the limit of detection (Figure

Released dye / %

3.24). The data showed that the limit of detection was around ~0.5 µg (1 µg/ml).
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Figure 3.23 Detection of TNF-α using dye loaded MSNs. The release study in the absence
and presence of TNF-α. The released dye was significant in the presence (red line, filled circles)
of TNF-α, while negligible release was found in the absence (black line, filled squares) of TNF-α.
All experiments were performed in triplicate.
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Figure 3.24 The limit of detection for TNF-α. Different concentration of TNF-α were used
to detect the release in different time points (Control was shown in black color, filled squares; 0.5
µg TNF-α was shown in red line, filled circles; 1 µg TNF-α was show in blue line, filled up
triangles; 3 µg TNF-α was shown in purple line, filled down triangles). As the concentration of
TNF-α increases, the released dye will increase. The limit of detection was ~0.5 µg (1 µg/ml). All
experiments were performed in triplicate.
3.5

Conclusion
IBD is an inflammatory disease of the gastrointestinal tract. IBD patients have to visit

their physicians regularly to monitor inflammation and the typical procedure is endoscopy, which
causes significant distress and discomfort to the patient. Additionally, inflammatory flareups have
been determined to a variety of reasons, that includes stress, environmental factors, etc. which
makes dosing of medication difficult for personalized medicine. If suitable biomarkers were
identified in ex-vivo body fluids, it would lead to an increase in research efforts to develop POC
diagnostics. Here, we investigated the association between fecal MMP-9 and serum TNF-α level
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due to inflammation using an established IL10-/- mouse model that has been used to determine
IBD severity.245, 248 We found that these two biomolecules could be potentially used to monitor
inflammation in IBD. We also developed assays to detect fecal MMP-9 and serum TNF-α. While
the assays establish proof of concept that dye loaded MSNs can be used to monitor biomarker
concentration and could be readily developed to POC diagnostics that requires minimal sample
pretreatment, the limit of detection is higher. Efforts to improve sensitivity is currently underway
and these studies will be reported soon.
In the future, we will work on the amplification of this system. We are going to load
cysteine instead of dye into MSN, the released cysteine can activate caged papain and produce a
series of enzymatic reaction to amplify the signal. Papain is a proteolytic enzyme that has a thiol
group at its active site, which can be modified conveniently by mixing with methyl
methanethiosulfonate to generate caged papain (papain-S-S-CH3).249 The thiol group from
cysteine can react with caged papain result in the formation of active papain (papain-SH).250 The
active form of papain can catalyze chromogenic substrate and release fluorophore (Figure 3.5).
According to this method, the signal can be amplified.

Figure 3.25 Amplification of MSN signal.
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3.6

Experimental
3.6.1

MMP-9 and TNF-α concentration detection.

Materials: InnoZyme™ Gelatinase (MMP-2/MMP-9) Activity Assay kit (CBA003),
Recombinant, active human MMP-9 (PF140), MCM-41 type mesostructured silica (CAS#: 763186-9), (3-Aminopropyl) triethoxysilane (APTES, CAS#: 919-30-2) were purchased from Sigma.
TNF alpha Mouse ELISA Kit, High Sensitivity (Catalog#: BMS607HS) was purchase from
Thermo Fisher Scientific. Wild mice and IL10-/- mice serum, fecal samples were obtained from
Didier Merlin (Georgia State University)’s lab.
MMP-9 and TNF-α activity detection: 1000 ng/ml, 50 µl of MMP-9 enzyme was
prepared, then 2-fold serial dilute 6 times with PBS buffer in 96 well plate. Followed by adding
30 µM, 50 µl MMP-9 substrate. The mixture was incubated in 37 ℃ for 3 h, then was detected
fluorescence at 320/405 nm for 3 times. The standard curve for MMP-9 activity was shown in
Figure 3.26A. TNF alpha Mouse ELISA Kit, High Sensitivity was used for TNF-α activity
detection and the manufacturer’s instructions was followed for the experiment. The standard curve
for TNF-α activity was shown in Figure 3.26B.

A

B
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Figure 3.26 Standard curve. A. Standard curve for MMP-9 activity; B. Standard curve for
TNF-α activity. All experiments were performed in triplicate.
Assays with mice fecal and serum samples: The mice feces were prepared as 100 mg/ml
solution in PBS buffer, vortexed for 15 min, centrifugated in 14,000 g for 10 min and the
supernatant was collected for experiment. Next, 20 µl of fecal sample was mixed with MMP-9
substrate to a total volume of 100 µl, MMP-9 substrate final concentration was 15 µM. The mixture
was incubated in 37℃ for 3 hours and fluorescence was detected at 320/405 nm.
Mice serum samples 50 µl were used for TNF alpha Mouse ELISA Kit, High Sensitivity,
Thermo Scientific, to detect TNF-α concentration in accordance with the manufacturer’s
instructions.
3.6.2

Fabrication and characterization of MSNs.

I. Chemical synthesis
General: Chemical reagents were of analytical grade, used as supplied, without further
purification unless indicated. Analytical thin layer chromatography (TLC) was performed on silica
gel 230-400 mesh (Silicycle, Quebec City, Canada). Plates were visualized under UV light, and/or
by staining with acidic CeH8Mo3N2O12, followed by heating. 1H and 13C NMR spectra were
recorded on Bruker 400 MHz spectrometer. Chemical shifts are reported in δ (ppm) units using
13C and residual 1H signals from deuterated solvents as references. Spectra were analyzed with
MNova® (Mestrelab Research, Escondido, CA, USA).
Abbreviations: Sodium azide, NaN3; Dimethylformamide, DMF; (3-Aminopropyl)
triethoxysilane, APTES; MCM-41 type mesostructured silica, MCM-41; 2-(1H-benzotriazol-1yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, HBTU; N, N-Diisopropylethylamine,
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DIPEA; Dichloromethane, DCM; Methanol, MeOH; Sodium sulfate, Na2SO4; Sodium
metabisulfite, Na2S2O5.

Scheme 3.1 Reagents and Conditions: (a) NaN3, DMF, 80 °C, 12 h, 98%;251 (b) 1M Jones’
Reagent, acetone, 0°C-RT, 3 h, 99%;251 (c) APTES, HBTU, DIPEA, DCM, RT, 16 h, 50%.252

6-azidohexan-1-ol. To the solution of 3-1 (2.00 g, 11.86 mmol) in anhydrous DMF (10
mL) was added NaN3 (1.08 g, 16.60 mmol), the reaction was stirred at 80 °C for 12 h. After
completion of the reaction (TLC), the mixture was washed with deionized water, and the aqueous
layer was extracted with ethyl acetate. The organic layers were collected, dried over Na2SO4, and
concentrate under reduced pressure to afford 3-2 as a colorless oily material (1.96 g, 11.62 mmol,
yield=98%).

6-azidohexanoic acid. To the solution of chromium (VI) oxide (0.99 g, 9.92 mmol) in
deionized water (7.72 mL), concentrated sulfuric acid (2.20 mL) was added dropwise at 0℃ to
form 1M Jones’ Reagent. The Jones’ Reagent was added to the solution of 3-2 (0.35 g, 2.48 mmol)
in anhydrous acetone (7.72 mL) at 0 °C. The reaction was stirred at RT for 3 h. After completion

81
of the reaction (TLC), the mixture was washed with saturated Na2S2O5 solution and 2M HCl at 0
°C, and the aqueous layer was extracted with ethyl acetate. The organic layers were collected,
dried over Na2SO4, and concentrated to afford 3-3 (0.39 g, 2.46 mmol, yield=99%).

6-azido-N-(3-(triethoxysilyl)propyl)hexanamide. 3-3 (0.39 g, 2.46 mmol), HBTU (1.13
g, 2.98 mmol) and DIPEA (1.30 mL, 7.44 mmol) were successively dissolved in anhydrous
CH2Cl2, and stirred under N2 at RT for 30 min. Then APTES (0.70 mL, 2.98 mmol) was added,
the mixture was stirred at RT for 16 h. After completion of the reaction (TLC), the crude product
was purified by column (EtOAc:Hexane=1:1) to afford 3-4 as a colorless oily material (0.45 g,
1.25 mmol, yield=50%). 1H NMR (600 MHz, CDCl3) δ 5.82 (s, 1H), 3.82 (q, J = 7.0 Hz, 6H),
3.37 – 3.17 (m, 4H), 2.17 (t, J = 7.5 Hz, 2H), 1.96 (s, 1H), 1.78 – 1.55 (m, 6H), 1.41 (ddd, J = 18.6,
8.9, 6.1 Hz, 2H), 1.23 (t, J = 7.0 Hz, 9H), 0.73 – 0.58 (m, 2H).
II. Fabrication and characterization of MSNs.
Synthesis of the MMP-9 substrate gated material. 6-Azido-N-(3-(triethoxysilyl) propyl)
hexanamide was synthesized according to Scheme 3.1. The compound was characterized
completely by

1

H-NMR and

13

C-NMR. Next, we modified MSN with 6-azido-N-(3-

(triethoxysilyl) propyl) hexanamide. To this end, MCM-41 (0.1 g) was suspended in dry toluene
(80 ml), following which 6-azido-N-(3-(triethoxysilyl)propyl)hexanamide (0.75 ml) was added
and refluxed for 24 hours under nitrogen atmosphere253. The mixture was centrifuged at 10,000
rpm for 10 min, washed with toluene and methanol, and dried under vacuum to obtain MSN-N3.
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To load the dye, a large excess of dye was used. 15 mg of MSN-N3 was suspended in 2.5 ml of 2
mg/ml rhodamine b solution in DMF and stirred for 24 h. Next, 15 mg of peptide P, copper sulfate
(11.24 mg) in 100 µL DI water, sodium ascorbate (17.83 mg) in 100 µL DI water and 500 µL tbutanol were added, and a microwave reaction was performed at 90℃ for 30 min.254 The solution
was centrifuged at 10,000 rpm for 5 min, washed with DI water and dried under vacuum to
generate MSN-P. This material was washed extensively for twenty times was DI water followed
by PBS buffer over ten days to remove dye that is adhered on the surface.
Synthesis of the TNF-α antibody gated material. First, to modify the surface of MSN
with APTES, purchased MCM-41 (0.1 g) was suspended in dry toluene (80 ml) to which APTES
(0.75 ml) was added, and refluxed for 24 hours under nitrogen atmosphere253. After the reaction,
the mixture was centrifuged at 10,000 rpm for 10 min, washed with toluene and methanol, and
dried under vacuum to generate MSN-NH2. The zeta potential of MSN-NH2 was +14 mV while
that of MSN was -28 mV (Figure 3.27), confirming that the surface was covered by the amino
group. Next, 10 mg MSN-NH2 was suspended in 2 ml of 200 µM fluorescein PBS solution and
stirred for 24 hours, followed by the addition of 80 µl of 0.5 mg/ml TNF-α antibody and stirring
for 6 hours. The mixture was centrifuged at 10,000 rpm for 5 min, washed with PBS buffer, and
dried to generate MSN-Ab. As described previously, this material was washed extensively to
remove excess dye.
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Figure 3.27 Zeta potential of MSN and MSN-NH2. The black column represents the zeta
potential of MSN is -28 mV, while red column represents the zeta potential of MSN-NH2 is +14
mV. It confirms that the surface of MSN-NH2 was cover by amino group. All experiments were
performed in triplicate.
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CHAPTER 4 PROTEIN-GLYCAN INTERACTIONS: BINDING OF DIFFERENT
NOROVIRUS VLPS TO A PANEL OF HISTO-BLOOD GROUP ANTIGENS

* Most of the work described in this chapter has been submitted in two publications and one more
publication is in preparation:
1. Abasaheb N. Dhawane, Marta Diez-Valcarce, Bharat P. Gurale, Hieu Dinh, Jan Vinjé*,
and Suri S. Iyer*. Synthesis and Evaluation of Biotinylated Bivalent HistoBlood Group
Antigens for Capturing Human Noroviruses. Bioconjug Chem 2016, 27 (8), 1822-9.
2. Amy E. Kirbya*, Yvonne Kienast, Milagros Aldeco, Molly Steele, Abasaheb Dhawane,
Dandan Liu, Xikai Cui, Amrita Das, Suri S. Iyer* and Christine L. Moe. Snow Mountain
Virus Recovery by Synthetic Human Histo-Blood Group Antigens is Heavily Influenced by
Matrix Effects. Scientific Reports, 2020, 10 (1), 4661.
3. Dandan Liu, Abasaheb N. Dhawane, Xiaohu Zhang, Xikai Cui, Marta Diez-Valcarce, Jan
Vinjé, Xinqiu Yao, Donald Hamelberg and Suri S. Iyer*. Protein-Glycan Interactions:
Binding of Different Norovirus VLPs to a Panel of Histo-Blood Group Antigens. Manuscript
in preparation.

4.1

Norovirus Introduction
4.1.1

Norovirus epidemiology

Human noroviruses are the major cause of most epidemic outbreaks of gastroenteritis,
leading to 218,000 deaths in children younger than five and 1.1 million hospitalizations worldwide
each year.255 Norovirus outbreaks typically occur in the winter months. . People infected by
norovirus have severe nausea, vomiting and watery diarrhea within 12–24 hours exposure of
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norovirus, which may lead death to severely immunocompromised people.256 The outbreak was
first described by Zahorsky, J. as ‘winter vomiting disease’ in 1929 due to its seasonal incidence
and vomiting symptom.257 The main route transmission is fecal-oral transmission, other
transmission routes including food, water and environment contamination.255 Waterborne
outbreaks was first reported by Kaplan, J. E. et al. in 1982.258 Multiple water systems linked with
norovirus outbreaks, including municipal water systems, commercial ice consumption and potable
water at camps.259-261 To rapidly identify norovirus break, a criteria has been developed by Kaplan,
J. E. et al..262 It includes vomiting in more than half of symptomatic cases; mean or median
incubation period of 24 – 48 hours; mean or median duration of illness of 12 – 60 hours; no
bacterial pathogen isolated in stool culture.
Table 4.1 The criteria to identify norovirus outbreaks. The table is taken from publisher
with permission.262
Criteria to identify norovirus outbreaks

4.1.2

1

vomiting in more than half of symptomatic cases

2

Mean or median incubation period of 24 – 48 hours

3

Mean or median duration of illness of 12 – 60 hours

4

No bacterial pathogen isolated in stool culture

Norovirus structural proteins

Norovirus belongs to Caliciviridae family, it has a positive single-stranded RNA, which
encodes three open reading frames (ORFs).263 ORF1 encodes the nonstructural proteins, ORF2
and ORF3 encodes structure proteins: major capsid protein VP1 and minor structural protein VP2
respectively.264
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Major capsid protein VP1
There are 90 dimers of VP1 on the norovirus virion, which is composed of 530 – 555 amino
acids.265 It forms a T = 3 icosahedral symmetry virion with 180 molecules of VP1. VP1 contains
two conserved domains, which defines strain specificity. And it consists two domains: shell (S)
domain and protruding (P) domain, P domain can be further divided into P1 and P2 domain
(Figure 4.1).266 The S domain forms a scaffold centered the viral RNA, whereas P domain stabilize
the capsid and interact with cells. It was found that P2 domain plays an important role in binding
histo-blood group antigens in the process of infection.267 It is difficult to proliferate norovirus in
human cell culture268, therefore, VP1 was used to assembles virus-like particles (VLPs) that mimic
norovirus particles. To prepare VLP, a recombinant baculovirus containing VP1 coding genes was
cultured in mammalian or insect cells.269 The expressed recombinant protein self-assembles into
VLP spontaneously, which preserve the structure and antigenicity of virions.

P2 domain

P1 domain

S domain

Figure 4.1 Structure of VP1 monomer downloaded from NIH PDB database and PyMOL
was used to show different domains (PDB: 6OUT).270 P2 domain is shown in blue color, P1 domain
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is shown in purple color and S domain is shown in green color. There is a N-terminal arm shown
in yellow color.
Minor capsid protein VP2
There are few copies of VP2 on the norovirus virion, which is consist of 208 – 268 amino
acids. Although it is not necessary for recombinant VLP

271

, it was found that absence of VP2

decreases the stability and size homogeneity of VLPs 272. If both VP1 and VP2 coding genes were
involved in the assembly of VLPs, the expression of VLPs increases.273 VP2 is also essential for
the production of infectious virions of feline calicivirus.274 The lack of VP2 crystal structure makes
it difficult to study more functions of it.
4.1.3

Histo-blood group antigens (HBGAs)

It was found that norovirus recognize human HBGAs as receptor when it infects humans.275
Different types of norovirus bind to HBGAs with high diverse patterns. Studies on the binding
patterns of norovirus with HBGAs are important for diagnostics and treatment of norovirus
infection.
Studies on the interaction between norovirus and HBGAs have concentrated on the ABO,
H, Lewis blood group antigens.276 Different blood group systems were formed by adding specific
carbohydrates to an oligosaccharide precursor that bind to lipids or proteins. Basically, there are
four types of core structures carry ABH antigen activity277 as shown in Figure 4.2. Type 1 and
type 2 precursors are linked to proteins or lipid linked oligosaccharides, type 3 are linked to
oligosaccharides, while type 4 are linked to lipids.278 Glycosyltransferases are responsible for the
synthesis of different types of antigens. Two different α(1,2) fucosyltransferases FUTI and FUTII
add a fucose to the precursor by α1-2 linkage to form H type antigen.279 FUTI comes from H gene
in hematopoietic tissues, which has a high preference for type 2 and type 4 precursor chains; while
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FUTII comes from Se gene in secretory tissues, which has a high preference for type 1 and type 3
precursor chain.279 A type antigen was synthesized by adding galactosamine to the H type antigen
by α(1,3) N-acetylglucosaminyltransferase. Whereas, B type antigen was synthesized by adding
galactose to the H type antigen by α(1,3) galactosyltransferase.280 Synthesis of Lewis (Le) antigen
involves another type of fulcosyltransferase, for instance, Le a and x are synthesized by adding a
fucose to N-acetylglucosamine with α1-4 or α1-3 linkage to the type 1 and type 2 precursor chains.
Whereas, Le b and y are synthesized by adding a fucose to the same position to with α1-4 or α1-3
linkage to the type 1 and type 2 H type antigen.281 The biosynthetic pathway was shown in Figure
4.3.

Figure 4.2 Four types of precursor structures carrying ABH antigen. The differences
between these structures were shown in different color, R represents lipid or protein. Type 1 shows
a Gal β1-3 GlcNAc β1-R structure; type 2 shows a Gal β1-4 GlcNAc β1-R structure; type 3 shows
a Gal β1-3 GalNAc α1-R structure; type 4 shows a Gal β1-3 GalNAc β1-R structure.
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Figure 4.3 Biosynthetic pathway for ABH and Lewis antigens. Yellow circle represents
galactose; yellow square represents N-acetylglucosamine; blue square represents NAcetylglucosamine; red triangle represents fucose. Figure is taken from publisher with
permission.282
4.1.4

Therapeutics of norovirus

There is no specific treatment for gastroenteritis caused by norovirus. Most people will
recover in few days by preventing dehydration and controlling symptoms. One effective way to
prevent norovirus outbreak is a vaccine. In recent years, several studies have been done to develop
vaccine against norovirus by VLPs, however, a validated vaccine is still elusive.
4.1.5

Current diagnostics for norovirus

Norovirus antigen detection
Enzyme immunoassays. Several enzyme immunoassays (EIAs) have been developed
commercially to detect norovirus in fecal samples, IDEIA Norovirus (Thermo Fisher Scientific,
Basingstoke, UK) and Ridascreen Norovirus (R-Biopharm, Darmstadt, Germany) are most
commonly used.283,

284

Noroviruses are genogroup and genotype wildly diverse, the antibody
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applied in the EIAs should be able to cross react with different genogroups and genotypes. Several
studies have evaluated the value of commercial IDEIA Norovirus to detect norovirus in fecal
samples.285-287 The results showed that the sensitivity and specificity were ranged from 38.0% to
78.9% and 85.0% to 100.0% respectively. Similar as IDEIA Norovirus, the sensitivity and
specificity of Ridascreen Norovirus were 32 – 92% and 65 – 100% respectively.287-290 Multi
samples test can increase the detection sensitivity of EIAs. Costantini, V. et al. have proved the
sensitivity of IDEIA Norovirus increased from 44% by detecting 3 samples to 77% by detecting 5
samples per outbreak.285 Therefore, a minimum of 6 outbreak samples is recommended for
norovirus outbreak management.291 The Ridascreen Norovirus third-generation test was approved
by Food and Drug Administration (FDA) in 2011 to investigate norovirus outbreak. Compared to
RT-PCR, enzyme immunoassay is more convenient and saving time.
Rapid immunochromatographic assays. A number of rapid immunoassays have been
developed to detect norovirus antigen by lateral-flow immunochromatographic assays, which may
provide as a POC tool. Ridaquick Norovirus (R-Biopharm, Darmstadt, Germany) and SD Bioline
Norovirus (Standard Diagnostics, Inc., Kyonggi-do, South Korea) are most commonly used
commercially available rapid tests.292, 293 Studies have evaluated the sensitivity and specificity of
Ridaquik Norovirus were 17 – 83% and 88 – 100% respectively.292-294 For SD Bioline test, the
sensitivity and specificity were 23 – 92% and 99 – 100% respectively.295-297
Molecular diagnostic tests
RT-PCR. RT-PCR is the golden standard for detection of different types norovirus. The
first-generation RT-PCR assay used several primers based on only the first norovirus genome.298,
299

It didn’t perform well because the wild diversity of norovirus. The second-generation utilized

sequences from different norovirus strains and the primers were designed by conserved regions of
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the viral genome, which works well.300, 301 other methods include, real time RT-PCR286, 302,
commercial RT-PCR303,

304

and multiplex PCR/RT-PCR305,

306

. Those methods improved the

sensitivity and specificity of detection, and multiplex PCR/RT-PCR can detect hundreds of
samples at one time. Overall, molecular test is more accurate than antigen test, however, the cost,
need for trained personnel and equipment is prohibitive for low resource settings.
Summary
Taken together, there is a great need to develop alternate methods to accurately detect
norovirus at POC. If POC were available, it would decrease morbidity and limit economic damage
in an outbreak situation. Infected people could be isolated if identified early and economic activity
could resume. As a first step towards the development of POC diagnostics, we studied the
interactions between norovirus VLPs and its receptor, histo-blood group antigens. Our goal is to
identify suitable glycoconjugates that could be used to capture norovirus in stool samples. Once
identified, these glycoconjugates could be potentially be used in lateral flow assays similar to home
pregnancy tests. A unique advantage of glycans is that these molecules can be produced in large
quantities, are very stable in ambient conditions and can be characterized completely using NMR,
mass spectroscopy and HPLC. Additionally, unlike antibodies, these small molecules can be easily
and reproducibly conjugated to any diagnostic surface like nitrocellulose membranes or beads.
To identify suitable glycans that could bind to HBGAs, we choose SPR as the biophysical
technique as this is a label free technique that is widely used to identify drugs, receptors and other
small molecules. Described below is a primer on SPR, followed by a brief discussion on the
synthesis of the glycans and the SPR studies. Also included computation studies that delineate
some of the complex interactions between HBGAs and the synthetic glycoconjugates.
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4.2

SPR Introduction
4.2.1

Principle of SPR

SPR is a label-free biosensing technique, and it can monitor the binding interaction in real
time. All the interactions happen in the sensor chip, as shown in Figure 4.4. There’s a prism in the
bottom, a very thin gold was attached on the surface of the prism. The gold surface was coated
with dextran or streptavidin, which can bind with ligand tightly. When the analyte flow through
the ligand surface, it can catch analytes and give a signal. The principle of SPR involves total
internal reflection and evanescent waves and surface plasmon.307 When the light comes from
higher refractive index medium to the lower refractive index, the total internal reflection can
happen in the higher refractive index medium. This causes the formation of evanescent waves in
the lower refractive index medium. The evanescent wave is enhanced when a gold film was put in
the interface of two mediums and penetrate the gold film. The evanescent wave can excite the
electron on the gold film, which makes the energy transfer from photon to metal electron. This
phenomenon is called surface plasmon resonance. When it happens, the intensity of reflected light
reduces, which can be captured by detector and express it as SPR response unit (RU) (Figure 4.5).
When different analytes are injected to the solution, the refractive index of upper medium changes,
the resonance angle θ will shift accordingly, which is detected as SPR signal (Figure 4.6).
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Figure 4.4 Principle of SPR. The light source travels from prism to solution, the total
internal reflection will happen in a certain angle. In this condition, the energy is transferred from
photon to gold electron and results in the formation of surface plasmon resonance wave. Then a
reduced reflection light beam can be detected by detector. When the analyte is injected in the
solution and flow through the surface, the refractive index will change, which makes the change
of refection angle. Figure is modified from publisher with permission.16
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Figure 4.5 SPR response unit changes as analytes binding and un-binding. When the buffer
flow through the gold surface, it is shown as baseline in SPR. Continuous injection of analyte
solution increase the RU, shown as association phase. After the injection stops, the RU decreases,
which is shown as dissociation. Following, the regeneration solution is used to remove the bound
analyte from the surface, the RU will go back to baseline and ready for next analyte to bind.

Figure 4.6 SPR signal. The refractive index in the medium when analytes attached to the
gold surface. The angle of reflection will change accordingly, which can be detected by detector
and expressed as SPR signal response unit (RU). Figure is modified from publisher with
permission.308
4.2.2

Ligand immobilization

There are different types of chips coated with different materials on the surface available.
Overall, they can be divided into two groups: covalent coupling sensor chips and capture coupling
sensor chips. On the surface of covalent coupling sensor chips, they were coated with
carboxymethylated dextran or no surface modification. Whereas, on the surface of capture
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coupling sensor chips, they were coated with streptavidin, nitrilotriacetic acid (NTA), hydrophobic
monolayer or lipophilic dextran. (Table 4.2)
Table 4.2 Different type of sensor chips and their applications.
Sensor types

Sensor surface

Covalent coupling Gold

Biocore chips

Applications

J1

Surface

sensor chips

interaction

and

custom designs
Carboxymethylated

CM3,

CM4, Protein-protein

dextran

CM5, CM7

interaction

and other molecules with
amino groups

Capture coupling Streptavidin

SA

Capture biotinylated ligands

sensor chips

NTA

Capture poly-histidine tagged

NTA

ligands
Hydrophobic monolayer

HPA

Capture lipid monolayers

Lipophilic dextran

L1

Capture liposomes and lipid
bilayers

For gold surface chips, sulfur and gold interaction is the most commonly used to
immobilize ligand directly to gold surface. The thiol group will form strong bond with gold
automatically, and the rest space of gold can be covered with thiolate PEG. Therefore, cysteine is
widely used in the protein or peptide immobilization. By immobilizing protein, it can be used for
protein-protein interaction.309, 310 The surface of CM chips are coated with carboxymethylated
dextran, which can interact with amino groups in protein or other molecules. Several intermediates
are used to couple with exposed amino groups, such as aldehyde, epoxide and N-Hydroxy
succinimide (NHS).311 With covalent immobilization, the proteins immobilized are hardly
inactivated by capture coupling, and the proteins are not necessary to be pure. Moreover, the
covalent bond is strong, hard to dissociate in the process of regeneration.312
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Capture coupling immobilization is based on the modification of the sensor chip to capture
special tag modified proteins or molecules. Ligands are coated to the surface of gold and utilize
the specific interactions between ligands and tags to immobilize target proteins or molecules.
Streptavidin coated SA chips are widely used as non-covalent immobilization due to the high
binding affinity between biotin and streptavidin (Kd ~10-14 M).313 Some other affinity pairs have
been used for the immobilization, such as chips coated with NTA is specific for histidine tag314,
coated glutathione is specific for S-transferase315.
4.2.3

SPR applications

SPR has become a powerful technique in binding affinity detection. A lot of molecules can
be involved in this detection, such as proteins, carbohydrates, lipids, nucleic acids, cells and small
molecules. SPR is also used in other applications, including molecular interaction, conformational
change analyses, mutation detection, drug and biomarker discovery.
SPR is widely used in the binding affinity analysis for different molecules, such as
antibody-antigen316, enzyme-substrate317, ligand-receptor318,

319

, biomarker binding and drug

discovery320. It also be used for determination of binding kinetics. The Langmuir model is widely
used binding model to describe the interaction between ligand and analyte. Reaction rate (ka and
kd) and equilibrium constant (KD) are used to describe the interaction as shown in the following
equation:
A+B

ka
kd

AB

The association constant ka represents the formation rate of the complex AB, whereas the
dissociation constant kd represents the dissociation rate of AB. The detailed description of common
constants is shown in Table 4.3.
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Table 4.3 Description of relevant kinetic parameters in SPR. The figure is taken from
publisher with permission.321
Constant

Definition

Description

Unit

Association rate

A+B

Formation rate of the complex AB:

M-1s-1

AB

constant, ka

number of AB formed per unit time
at unit concentration of A and B

Dissociation rate

AB

constant, kd

A+B

Dissociation rate of AB: number of

s-1

AB dissociating per unit time

Equilibrium association

[AB]/[A][B] = ka/kd Association affinity

M-1

[A][B]/[AB] = kd/ka Stability of AB

M

constant, KA
Equilibrium
dissociation constant,
KD

SPR can also be used verify conformational changes and mutation of proteins. SPR signal
is strongly affected by optical thickness of metal film and the refractive index changes near the
metal surface. When a protein goes through a conformational change, the optical indicators are
also affected, which can be detected by SPR detector. Several studies have been used SPR to
monitor structural transition in protein-small molecules interactions322, proteins changes in
different conditions323,

324

. Han, S. H. et al. have detect mutation of protein p53 with SPR

techinique.325 It showed the RU of wild p53 was 4.7 higher than mutated protein each 100 nM.
4.3

Results and Discussions
4.3.1

Synthesis of the HBGA glycoconjugates: (Done by Dr. Abasaheb N. Dhawane,
a former postdoctoral fellow in our group)

We developed biotinylated bivalent H, A and B-type glycoconjugates (Figure 4.7). The
structure consists of two glycan headgroups, an aromatic scaffold that is relatively easy to
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synthesize and a biotin, which allows conjugation to any streptavidin-coated surface. The spacers
for these constructs were chosen to span the length of the binding sites in a P dimer, although we
note that the glycan headgroups from a single glycoconjugate could bind to binding sites from two
P subunits, which are not part of the P dimer.
The synthesis of the bivalent biotinylated H, A and B-type saccharides, and the scaffold is
shown in schemes and the structures were confirmed by NMR. Our initial strategy was to
synthesize the tri/tetrasaccharides bearing an azide group, followed by coupling with the alkyne
bearing scaffold using Huisgen 1,3-dipolar cycloaddition conditions. The synthesis was completed
after conjugation to an activated biotin, followed by deprotection of all protecting groups;
however, this approach led to poor yields. We adopted an alternate strategy, where we coupled the
biotin to the alkyne bearing scaffold before the cycloaddition reaction with tri/tetrasaccharides
bearing an azide group followed by deprotection of protecting groups
Described in Scheme 4.1 is an example of the complete synthesis of one of the target
molecules. The details of the synthesis along with the complete characterization can be found in
our publication (Dhawane, A. N. et al. Bioconjugate Chemistry).326 Using this approach, a panel
of chemically well-defined biotinylated glycoconjugates were synthesized and characterized.
(Figure 4.7)
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Figure 4.7 Structures of the bivalent biotinylated H, A and B-type glycoconjugates. The
blue ellipse represents the glycan headgroup and the spacer is a six-carbon spacer. The synthesis
and characterization of most of the compounds has been reported in the Biconjugate Chemistry
paper.326 Figure is taken from publisher with permission.326

101

4-2
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4-7
4-8
4-9

4-10

4-6

4-11

4-5

4-12

H1

4-13

Scheme 4.1 Reagents and Conditions: a) 6-chloro hexanol, TMSOTf, DCM, 0℃-rt, 2h,
90%; b) i) NaOCH3, MeOH, rt, 30 min, 85%; ii) PhCH(OCH3)2, CSA, ACN, rt, 3α (28 %) and 3β
(41 %); c) i) TMSOTf, DCM, -40℃, 2h; ii) NaOMe, MeOH, rt, 1h; d) PivCl, pyridine, 45℃, 45
min., 75%; e) TMSOTf, Et2O:DCM, -10℃, 60%; f) Zn dust, CuSO4, Ac2O, AcOH, rt, 3h, 75% g)
i) Pd(OH)2/C, H2, ethyl acetate, rt, 4h; ii) Pyridine, Ac2O, DMAP, 12h, 66% over two steps; h)
NaN3, DMF, 80℃, 90%; i) Cupric sulfate, Sodium ascorbate, t-BuOH:H2O (7:3), rt, 24h, 80%; j)
NaOMe, MeOH, rt, 12h, 75%.
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4.3.2

SPR binding patterns for antigens

Next, we used SPR to detect the binding between glycoconjugates and VLPs. Biosensor
sensor SA chip was used for the binding detection. The surface of SA chip was coated with
streptavidin, which has very high binding affinity with biotin (Kd ~ 10-14 M).313 The biotinylated
antigens can be immobilized on the surface by binding with streptavidin. Afterwards, VLP can
flow through the surface of the chip, if the VLP can bind with the antigens, the signal will increase,
if the VLP does not bind with the antigens, the signal will not increase. After the binding
experiment, the bound VLP can be removed by harsh condition, such as glycine solution with pH
= 2.5. This step is called regeneration, which can move all the bound VLPs and bring the signal to
the baseline. Hence, the chip can be reused to bind another VLP. The experiment design is shown
in Figure 4.8.

Figure 4.8 Experimental design for detecting binding affinity of VLPs and biotinylated
carbohydrate. The surface of SA chip was coated with streptavidin, biotinylated carbohydrate can
bind with streptavidin with very high binding affinity. After immobilized with biotinylated
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carbohydrate, VLP-1 was flow through the surface to detect the binding affinity with the surface
carbohydrate. Followed by regeneration to remove the bound VLP-1, the surface carbohydrate
will be free to bind next VLP.
6 types of VLPs (GI.3, GII.2, GII.3, GII.4 New Orleans, GII.4 Sydney, GIV.1) were used
to access the binding with the panel of glycans shown in Figure 4.7. The binding results for each
VLP were shown in Figure 4.9. VLPs at 100 µg/ml concentration was injected for 300 seconds
with flow rate of 5 µl/min. The increase in RU after 300 seconds is given in Table 4.4. The results
showed that GI.3 VLP can bind with A4 with medium affinity (ΔRU = 689), while it binds with
B2 (ΔRU = 1878) and B2 (ΔRU = 1958) with very high affinity and very weak affinity with B3
(ΔRU = 22) but it doesn’t bind with H type antigens. The differences between A, B and H type
antigens is that H type antigens are trisaccharide, while A type antigens have one more Nacetylgalactosamine attached in the end, B type antigens have one more galactose attached in the
end. GII.2 VLP binds to A1 (ΔRU = 50) and A3 (ΔRU = 78) with weak affinity, no binding with
B type and H type antigens. GII.3 VLP doesn’t bind with any antigens. GII.4 New Orleans binds
to A1 (ΔRU = 31), A3 (ΔRU = 42) and B1 (ΔRU = 148) with weak affinity, no binding with other
antigens. GII.4 Sydney binds to A2 (ΔRU = 168), A3 (ΔRU = 133) and B2 (ΔRU = 98) with weak
affinity, binds to A1 (ΔRU = 556) with medium affinity, binds to A4 (ΔRU = 2119) and B1 (ΔRU
= 1022) with high affinity. GIV.1 VLP binds to A3 with medium affinity (ΔRU = 251), no binding
with other antigens. Therefore, to further study the relations between binding sites and binding
affinity of these two VLPs, we did computational calculation for Molecular dynamics (MD)
simulations and binding free energy.
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D. GII.4 New Orleans VLP
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Figure 4.9 Six types of norovirus VLPs binding with 11 types of HBGAs. A. GI.3 VLP binds
to HBGAs. It shows GI.3 has low binding affinity with A4 type HBGA, very high binding affinity
with B1 and B2 type HBGAs, very low binding affinity with B3 type HBGA and no binding with
other HBGAs. B. GII.2 VLP binds to HBGAs. It shows GII.2 has very low binding affinity with A1
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and A3 type HBGAs, no binding with other HBGAs. C. GII.3 VLP binds to HBGAs. It shows GII.3
has no binding with any of the HBGAs. D. GII.4 New Orleans VLP binds to HBGAs. It shows GII.4
New Orleans has negligible binding with A1, A2 and A3, very low binding with B1, no binding
with other HBGAs. E. GII.4 Sydney VLP binds to HBGAs. It shows GII.4 Sydney has very high
binding with A4, mediate binding with B1, lower binding with A1, very low binding with A3, A4
and B2, no binding with other HBGAs. F. GIV.1 VLP binds to HBGAs. It shows GIV.1 has low
binding with A3, no binding with other HBGAs. All experiments were performed twice.
Table 4.4 The value of RU for VLPs and HBGAs binding.
ΔRU Value
HBGA
VLPs
s
GI.3

Gal

H1

H2

H3

A1

A2

A3

A4

B1

B3

B4

NAa

NA

NA

NA

NA

NA

NA

689

1878 1958 22

NA

GII.2

NA

NA

NA

NA

50

NA

78

NA

NA

NA

NA

NA

GII.3

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

31

NA

42

NA

148

NA

NA

NA

NA

NA

NA

NA

556

168

133

2119 1022 98

NA

NA

NA

NA

NA

NA

NA

NA

251

NA

NA

NA

B2

GII.4
New
Orleans
GII.4
Sydney
GIV.1
a

NA

NA

NA: ΔRU lower than 10.
4.3.3

Relative binding free energy for VLP and antigens (Done by Dr. Xinqiu Yao)

Molecular dynamics (MD) simulations and binding free energy calculations predict a rank
of VP1-glycan associations consistent with experiments. Multiple hundred-nanosecond time scale
simulations were performed, each for one of the VP1-glycan systems including Sydney-AIV,
Sydney (R373N)-AIV, Sydney-AII, and New Orleans-AIV. Surface Plasmon Resonance (SPR)
experiments show that the binding affinity between Sydney and AIV is strong while the affinity

107
of Sydney-AII or New Orleans-AIV is very weak. The Sydney (R373N) mutant was included to
test whether the single point mutation of the binding site residue Arg373 underlies the distinct AIV
binding affinities between Sydney and New Orleans. Principal Component Analysis (PCA) of the
simulation trajectories reveals overall distinct global conformations among the systems, where
major structural changes occur at both ligand binding and distal sites (Figure 4.10). Binding free
energy was calculated for each conformational snapshot from the trajectory of a particular system.
Statistics over all snapshots show that the binding affinity of Sydney-AIV is significantly higher
than that of Sydney-AII or New Orleans-AIV, consistent with the SPR experiments (Figure 4.11
A and Table 4.4). Sydney (R373N) displays a medium binding affinity for AIV, weaker than
wildtype Sydney but stronger than New Orleans. This suggests that the amino acid substitution at
R373 contributes to the distinct AIV binding affinities between Sydney and New Orleans but does
not fully account for the difference.

Figure 4.10 Principal component analysis (PCA) reveals distinct global conformations.
(A) Simulation-generated conformational snapshots (colored areas) are projected in the subspace
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spanned by the two principal components capturing the largest structural variance (PC1 and PC2;
the number in the axis label indicates the percentage of variance captured by the corresponding
PC). Probability density distributions of the conformational samples are represented as contour
lines. The sampled space of each simulation is outlined. (B) Collective motions (blue shaded areas)
represented by PC1 and PC2, respectively, mapped onto the VP1 homodimer (white cartoon)
bound with ligands (yellow licorice). Red spheres, sites of amino acid substitutions between Sydney
and New Orleans.

Figure 4.11 Molecular dynamics and binding free energy calculations indicate that
Sydney-AIV complex has the strongest ligand binding affinity and the most flexible binding site.
(A) Probability density distributions of relative binding free energy with respect to the mean
energy of Sydney-AIV under distinct VP1-glycan combinations. (B) Root mean square fluctuation
(RMSF) for each binding site residue derived from MD simulations. The dotted line indicates the
separation of protein and ligand residues. Two key residues showing the largest variation in RMSF
across systems are labeled. Inset, molecular graphic of the binding site with protein colored by
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RMSF and ligand colored by yellow. The ligand and flexible binding site residues are represented
as licorice. The sugar group distinguishing AIV and AII is highlighted with a black rectangle,
where the name of the sugar for AIV (AII) is labeled.
Table 4.5 Relative mean binding free energy with respect to Sydney-AIV (unit: kcal/mol;
T=300 K).

a

System

H

-TS

G

Sydney (R373N)-AIV

-0.140

1.403

1.263±0.072a

Sydney-AII

-3.180

7.436

4.256±0.064

New Orleans-AIV

-1.857

6.436

4.579±0.066

mean±SEM.

Binding free energy analysis suggests that the specific Sydney-AIV binding is driven by
entropic changes. The enthalpic and entropic part of the binding free energy display opposite
directions of changes from Sydney-AIV to the other combinations – in terms of mean interaction
energy (enthalpy) Sydney-AIV binding is the weakest; but the Sydney-AIV complex retains the
largest portion of its flexibility upon ligand binding, leading to the overall strongest binding free
energy due to a less loss in entropy of binding (Table 4.5). Energy decomposition on the basis of
binding site residues indicates that in spite of the overall similar pattern of VP1-glycan interactions
across systems, interactions around Arg373 and Gly393 are substantially altered upon either
mutations at the binding site or the sugar substitution in the ligand (Figure 4.12 & 4.13).
Intriguingly, Arg373 does not interact with the ligand directly (Figure 4.12) but the mutation at
this site affects interactions between the neighboring Asp374 and the ligand (Figure 4.13).
Consistent with the enthalpic analysis, the net interaction energy between the binding site of
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Sydney and AIV is the weakest. However, the unique interaction pattern in Sydney-AIV may result
in specific conformational dynamics that contribute to the enhanced entropy of the complex. To
test this hypothesis, we performed residue wise root mean square fluctuation (RMSF) analysis.
Results show that Sydney-AIV has the most flexible binding site, with largest difference of
fluctuation occurring at residues Arg373 and Gly393 (Figure 4.11B). Residues Arg373 and
Gly393 of Sydney are replaced with an asparagine and a serine, respectively, in New Orleans. In
addition, the location of the sugar group distinguishing AIV (GalNAc) and AII (GlcNAc) is close
to Gly393 (Figure 4.11B). These facts suggest that perturbation introduced by sequence variation
or binding of distinct ligands considerably affects the flexibility of the protein, which in turn alters
the overall entropy of the complex and ultimately the bind free energy. Intriguingly, although
Sydney (R373N) is only different by one-amino acid from the wildtype, it has a substantially
reduced flexibility at both Arg373 and Gly393, implying a dynamical coupling between the two
residues.
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Figure 4.12 The ligand interacts with binding site residues in an overall similar pattern
across systems. Interaction energies are decomposed on the basis of residues and the energies
belonging to binding site residues are shown.
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Figure 4.13 Interaction energies at specific regions are perturbed upon mutations or
binding distinct ligands. Interactions energies are decomposed on the basis of residues and the
relative energies, with respect to Sydney-AIV, belonging to binding site residues are shown.
4.4

Conclusion
The binding affinities between different norovirus VLPs and chemically synthesized

HBGAs were studied. Different VLPs have different binding patterns with HBGAs. While we
know that norovirus binds to HBGA glycans, the intricate details of binding is complicated because
of the shallow binding pockets of the norovirus.275 To further improve our understanding , we
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performed molecular dynamic simulations, where we varied the amino acid sequence of one VLP
and studied it’s interaction with two sets of glycoconjugates. Molecular dynamics (MD)
simulations and binding free energy calculations were used to predict the binding of GII.4 New
Orleans and GII.4 Sydney and contributions of binding site residues. The computational prediction
shows good correlations with SPR results. Single mutation was done for GII.4 Sydney, which
implies the importance of binding site R373 for the binding affinity. These results further illustrate
the reason for different binding affinities of VLPs. The differences in the binding affinities could
potentially be used in POC diagnostics. We found that there are subtle differences in the binding
affinities between a panel of HBGAs and different VLPs. We envision developing a microarray
with a library of unique chemically defined glycans at specific locations. Exposure to a panel of
norovirus genotypes would result in a fingerprint pattern of recognition, that could be used to
accurately identify norovirus including genotypes.
4.5

Experimental
4.5.1

SPR binding assay

Materials: Biacore T200 machine, series S sensor chip SA (The surface was conjugated
with streptavidin) and BIAdesorb solutions were from GE Healthcare Life Sciences company.
Norovirus like particles (VLPs) were got from Centers for Disease Control and Prevention (CDC),
biotinylated carbohydrates were synthesized in our laboratory. HBS-EP buffer was purchased from
GE Healthcare Life Sciences, used for the immobilization step. Phosphate buffered saline (PBS,
pH=7.4) was used for the VLPs and biotinylated carbohydrates binding step.
Immobilization: Immobilization was performed by streptavidin-biotin binding method in
the Biacore T200 machine. The SA chip was used with temperature setting of 25℃ and HBS-EP
running buffer. After cleaning the machine and inserting the chip, condition the sensor surface
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with consecutive 1 min 1 M NaCl in 50 mM NaOH solution for 3 times to remove the streptavidin
molecules that are not covalently attached to carboxymethyl dextran matrix. Followed by injection
of HBS-EP running buffer until the baseline is stable. Then prepare 2 µg/ml of H1, H2, H3
compound and 10 µg/ml of biotinylated polyethylene glycol (PEG) with HBS-EP buffer. H1, H2,
H3 compound were immobilized to channel 2, 3 and 4 separately until the resonance unit (RU)
increase 380 (flow rate: 10 µl/min), then biotinylated PEG was flow through channel 1, 2, 3, 4 to
block the remaining streptavidin sites. Channel 1 was covered with biotinylated PEG as control.
HBS-EP buffer was used to wash biotinylated compounds not attached with streptavidin until the
baseline is stable. A type and B type of HBGAs was immobilized in the same way. Biotinylated
PEG, A1, A2, A3 were immobilized in chip-2; biotinylated PEG, B1, B2, B3 were immobilized in
chip-3; biotinylated PEG, biotinylated galactose (Gal), A4, B4 were immobilized in chip-4.
SPR binding interaction: PBS running buffer was used for the binding process.
Biotinylated HBGAs immobilized SA chip was inserted to the machine, PBS buffer was used to
flow through the surface until the baseline is stable. Then GII.4-New Orleans VLP (100 µg/ml)
was injected for 300 seconds with flow rate of 5 µl/min. After injection, PBS buffer was allowed
to flow through for 10 min. Followed by regeneration with 10 mM glycine-HCl (pH=2.5) until it
gets back to baseline. After regeneration, next VLP can be used to bind with the chip. The same
procedure was used for the other VLPs and HBGAs binding.
4.5.2

Computational methods (Done by Dr. Xinqiu Yao)

Molecular dynamics simulations
MD simulations were performed using AMBER16327 along with the AMBER ff14SB force
field.328, 329 Reoptimized parameters for backbone peptide-bond torsion angles were employed.330
The GLYCAM06 force field331 was used for glycan molecules. Four systems were considered:
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Sydney-AIV, Sydney (R373N)-AIV, Sydney-AII, and New Orleans-AIV. The crystallographic
structure of GII.4 human norovirus VP1 (Sydney) homodimer in complex with 2-fucosyllactose
(PDB: 5J35)332 was used as the starting conformation for the simulations containing wildtype
Sydney VP1. The point mutation was introduced by simply replacing Arg373 with an asparagine
using PyMOL 1.8 (Schrödinger, LLC) for the Sydney (R373N)-AIV simulation. The starting
conformation of New Orleans was modeled using the SWISS-MODEL server with default
parameters.333 Arg and Lys were protonated, whereas Asp and Glu were deprotonated. The
protonation states of His residues were determined based on their pKa values at pH 7.0 calculated
using PROPKA 3.0334 implemented in PDB2PQR 2.1.1.335 The glycans AIV and AII were built
with GLYCAM-Web (http://glycam.org) and were used to replace the ligand in the crystal
structure by superimposing the common central galactose. Each system was solvated in an
octahedron periodic box filled with pre-equilibrated TIP3P336 water molecules, which extended at
least 10 Å from any surface of the complex to each box face. Na+ or Cl- counter-ions were added
to neutralize the systems. A series of energy minimization (EM) stages were performed, each
having 2000 steps of steepest decent followed by 3000 steps of conjugate gradient. Position
restraints were added for all atoms of the VP1-glycan complex with a force constant k=600
kcal∙mol-1∙Å-2 at the first stage of EM. Then, restraints were removed from the ligands but were
retained for the protein atoms. Six additional EM stages followed, where restraints were imposed
on the complex, but the force constant was gradually reduced from 600 to 0. The systems were
heated up from 100K to 300K in five stages of 500-ps MD, each having a 1-fs time-step and
position restraints for complex atoms (with k gradually reducing from 500 to 5). A further 1-ns
equilibration MD was performed with a 2-fs time-step and no restraint. Subsequent 500-ns
production MD was then performed under the same conditions as the equilibration, where the last
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300-ns data were analyzed. Constant temperature (300K; Langevin thermostat with collision
frequency γ=1.0 ps-1) and constant pressure (1 bar; Monte Carlo barostat with coupling constant
τp=1.0 ps) along with periodic boundary conditions were applied. The particle-mesh Ewald
summation method337 was employed to treat the long-range electrostatic interactions. For shortrange non-bonded interactions, a 9-Å cutoff was used. All bonds involving hydrogen atoms were
constrained with the SHAKE algorithm.338 Each snapshot in the trajectories was saved every 1 ps.
Binding free energy calculations
The standard binding free energy was calculated similar to the work by Minh339
∆𝐺 0 = −𝛽 −1 ln〈𝑒 −𝛽𝐵 〉 + 𝐶
𝛽
≈ ⟨𝐵⟩ − ⟨(𝐵 − ⟨𝐵⟩)2 ⟩ + 𝐶
2!
where <∙> represents an ensemble average, B is the binding energy for a single
conformational snapshot, =(kBT)-1 is the inverse of Boltzmann’s constant, kB, times the
temperature, T, and C is the free energy to confine the ligand to the binding site and is considered
to be a constant across systems. The second line of the equation employs a cumulant expansion
approximation up to the second order to simplify calculations of the exponential average. The first
term, <B>, represents the enthalpic change, ∆𝐻, upon ligand binding while the second term is
related to the entropic change, −𝑇∆𝑆. In the statistical analysis (Figure 4.10A), the binding free
energy for each simulation snapshot was computed by B plus the entropic term derived from the
ensemble. The single-point binding energy B was estimated with the Molecular
Mechanics/Generalized Born Surface Area (MM/GBSA) method implemented in AMBER16. Gas
phase energies were computed with the ff14SB force field.328, 329 The GBOBC II model340 and the
LCPO method341 were applied to calculate polar and nonpolar terms, respectively, of the solvation
energy. The salt concentration was set to be 0.1 M. The MMPBSA.py script342 of AMBER16 was
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employed to run calculations over every 100 frames of a simulation. Calculations were performed
for each binding site of the dimer separately and final results were derived from concatenated data
of the two binding sites (cumulatively 600-ns data for each system).
RMSF and PCA
Residue wise root mean square fluctuation (RMSF) was calculated using the CPPTRAJ343
command of AMBER16. Cartesian coordinates of equivalent binding site residues of the dimer
derived from MD simulations were concatenated. Before calculations, all simulation snapshots
were superimposed based on coordinates of main chain atoms (N, Cα, C, and O) of the binding
site. Then, mass-weighted average of atomic fluctuations of each residue was computed by
〈𝐹〉 =

∑𝑖∈𝐴 𝑓𝑖 ∙ 𝑀𝑖
∑𝑖∈𝐴 𝑀𝑖

where A contains all heavy atoms of the residue, Mi is the mass of atom i, and fi is the
fluctuation of atom i. The atomic fluctuation is defined by
𝑁

2
1
𝑗
𝑓𝑖 = √
∑‖𝑟𝑖 − 〈𝑟𝑖 〉‖
𝑁−1
𝑗=1

where N is the total number of simulation frames, rij is the position of atom i in frame j,
and <ri> is the mean position of atom i.
Principal component analysis (PCA) was performed on the Cartesian coordinates of
backbone atoms (N, C, and C) of VP1 dimer using CPPTRAJ. Prior to PCA, structures were
superimposed based on backbone atoms. The variance-covariance matrix characterizing the
correlated internal motions was then calculated and was diagonalized to obtain eigenvectors or
principal components (PCs). The structural variance along each PC is given by the corresponding
eigenvalue. The first two PCs capturing the largest structural variance were used to build the
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subspace where simulation trajectories were projected for the subsequent inter-conformer
relationship analysis. Molecular graphics were generated with VMD 1.9.3.344 All other figures
were made with Bio3D345, 346 and ggplot2.347
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